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Abstract
Prostate cancer (CaP) remains the most commonly diagnosed cancer and second leading cause of
cancer mortality among men in several ethnic groups in the United States. Lower CaP incidence
among Asian men has been attributed to increased intake of soy derived phytoestrogens (SDPs);
however, its association has not been extensively explored in U.S. men. The purpose of this
study was to determine the effect size of serum prostate specific antigen (sPSA) and serum
estradiol (sE2) following dietary SDP intervention. The study was based on an original
conceptual model that aims to avert early prostate tissue damage through identification of critical
prevention endpoints. Research questions examined the correlation between dietary SDPs and
sPSA and sE2 levels. This quantitative meta-analysis study used data abstracted from 8
randomized controlled trials yielding 530 participants ages 50-85. Outcome specific metaanalysis using the random effect model adjusted for heterogeneity and determined cumulative
effect size that favored intervention. Odds ratios established a positive correlation between intake
of dietary SDP and detection of serum SDP (sSDP) among treated groups. Positive correlations
between both dietary and sSDP with sE2 levels, and inverse correlations between both dietary
and sSDP with sPSA levels, were indicated among treated compared to placebo groups. Hedges’
g, correlation, and standardized mean difference statistics confirmed analyses. Implications for
positive social change include developing professional dietary standards to use SDPs for CaP
chemoprevention among U.S. and other men, as well as a medical option for treatment of CaP.
Further research exploring mechanisms of SDP action on hormones may be beneficial to men at
risk for CaP and individuals at risk for other cancers linked to changes in hormonal levels.

The Effect of Phytoestrogen Chemoprevention of Prostate Cancer
By

Ruel Slyfield Michelin
MPH, (Hons), American Public University, 2011
BS, Excelsior College, 2000

Dissertation Submitted in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Philosophy
Public Health

Walden University
May 2013

UMI Number: 3564132

All rights reserved
INFORMATION TO ALL USERS
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.

UMI 3564132
Published by ProQuest LLC (2013). Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against
unauthorized copying under Title 17, United States Code

ProQuest LLC.
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor, MI 48106 - 1346

Dedication
This work is dedicated to those who have faced the challenges of CaP diagnosis.
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been able to complete this work guided by scholars that care deeply about CaP and other
cancers and the need for valuable prevention strategies.

Acknowledgments
I am tremendously grateful and profoundly appreciative to my dissertation
committee members including chairperson and content expert Dr. Mary Lou Gutierrez,
methodology expert Dr. Xianbin Li, and the URR faculty member Dr. Michael Dunn.
Also, thanks to members of the University’s tutoring staff who have all contributed in
assisting to guide and direct this truly wonderful scholarly endeavor. Thanks to family,
relatives and friends that have always provided encouragement and support throughout
this process. I am certainly indebted for all the thoughtfulness extended and hope that the
results of this work will help to alleviate the suffering endured by those affected by this
disease. In addition, there is hope that the findings could possibly aid in defining both
preventative and therapeutic models to address issues relating to this disease and other
cancers. I hope that these findings might also open diverse avenues for further research
into other cancers that remain difficult to treat and affect the lives of millions globally.

Table of Contents
List of Tables ..................................................................................................................... iv
List of Figures ......................................................................................................................v
Chapter 1: Introduction to the Study....................................................................................1
Background of the Study ...............................................................................................1
Problem Statement .......................................................................................................11
Purpose of the Study ....................................................................................................12
Theoretical Base: Dual Prevention Intervention Model ..............................................12
Nature of the Study ......................................................................................................16
Research Questions and Hypotheses ...........................................................................16
Definition of Terms......................................................................................................18
Assumptions.................................................................................................................23
Limitations ...................................................................................................................24
Delimitations ................................................................................................................25
Significance of the Study .............................................................................................25
Summary and Transition ..............................................................................................27
Chapter 2: Literature Review .............................................................................................29
Overview ......................................................................................................................29
Literature Search Strategy............................................................................................29
Prostate and Hormone Refractory Cancer ...................................................................30
Epidemiology of Prostate Cancer ................................................................................39
Pathophysiology of CaP ...............................................................................................50
i

Dual Prevention Integrated Model ...............................................................................55
Estrogens and Cancer Etiology ....................................................................................58
Estradiol and PSA ........................................................................................................61
Evidence and Interpretation of CaP Development and Treatment ..............................62
Literature on Methodology of Studies on SDP and CaP .............................................64
Summary and Transition ..............................................................................................66
Chapter 3: Research Method ..............................................................................................68
Introduction ..................................................................................................................68
Research Design and Approach ...................................................................................69
Setting and Sample ......................................................................................................71
Instrumentation and Materials .....................................................................................71
Data Collection and Statistical Analyses .....................................................................73
Research Questions and Hypotheses ...........................................................................75
Internal and External Validity......................................................................................81
Summary and Transition ..............................................................................................82
Chapter 4: Study Findings .................................................................................................84
Characteristics of Randomized Clinical Trials ............................................................84
Statistical Meta-Analyses.............................................................................................88
Research Questions and Hypotheses ...........................................................................89
Summary and Transition ............................................................................................100
Chapter 5: Discussion, Conclusions, and Recommendations ..........................................101
Overview ....................................................................................................................101
ii

Interpretation of Key Findings ...................................................................................106
Study Limitations .......................................................................................................114
Recommendations for Future Research .....................................................................119
Implications for Social Change ..................................................................................121
Conclusion .................................................................................................................121
References ........................................................................................................................124
Appendix A: Manual and Study Inclusion Form .............................................................140
Appendix B: Effect Size Criteria Description .................................................................143
Appendix C: Effect Size and Study Coding Form ...........................................................144
Appendix D: Permission to Use REM Figure..................................................................146
Curriculum Vitae .............................................................................................................147

iii

List of Tables
Table 1. Events among Treatment and Placebo Groups used for OR Statistics.…….......87
Table 2. Odds Ratio and 95% C.I. between Dietary SDP and Serum SDP Levels……...91
Table 3. Odds Ratio and 95% C.I. between Dietary SDP and Serum PSA Levels .......... 92
Table 4. Odds Ratio and 95% C.I. between Dietary SDP and Serum E2 Levels………93
Table 5. Odds Ratio and 95% C.I. between Serum SDP and Serum PSA Levels ........... 94
Table 6. Odds Ratio and 95% C.I. between Serum SDP and Serum E2 Levels ............... 95
Table 7. REM Statistics for Computing Effect Size and Heterogeneity ........................ 103
Table 8. Interpretation of Hypotheses Testing Results Using REM Effect Size ............ 107

iv

List of Figures
Figure 1. Major Phytoestrogens found in Soy and the Influence on PSA and E2………...4
Figure 2. Likelihood (%) of Developing CaP over 3 Decades Based on Current Age,
2005–2007… ......................……………………….…...…………...…….……11
Figure 3. Dual Prevention Integrated Model…...…………..………………………..…..15
Figure 4. Healthy Prostate, nearby Organs and Internal Structures..………………..…..43
Figure 5. Prostate Gland with Identifiable Cancerous Tumor………………………...…44
Figure 6. Selection Process of RCTs Included in Meata-Analysis……………………....74
Figure 7. Random Effects Model……………………………….…….…………….…...77
Figure 8. Odds Ratios and 95% CI Effect Size of PSA Response to Phytoestrogen
5reatment using REM Meta-Analysis……………………………………..…96
Figure 9. Odds Ratios and 95% CI Effect Size of Estradiol Response to Phytoestrogen
Treatment using REM Meta-Analysis………………………………...……...97
Figure 10. Hedges’s g Assessment for Effect Size Statistic for PSA Response to
Phytoestrogen Treatment using REM Meta-Analysis ……………………..109
Figure 11. Hedges’ g Assessment for Effect Size Statistic for Estradiol Response to
Phytoestrogen Treatment using REM Meta-Analysis……………………..110
Figure 12. Correlational Assessment for Effect Size Statistic for PSA Response to
Phytoestrogen Treatment using REM Meta-Analysis……………………..112
Figure 13. Correlational Assessment for Effect Size Statistic for Estradiol Response to
Phytoestrogen Treatment using REM Meta-Analysis……………………..113

v

1
Chapter 1: Introduction to the Study
Background of the Study
Cancer is now the leading cause of mortality worldwide, with more than 7.6
million cases (World Health Organization [WHO], 2012). Prostate cancer (CaP) among
men in Western countries (Guy et al., 2008; Hill & Doyon, 2006; Jemal et al., 2007) is
significantly higher in incidence rate than the rate observed among men living in Asian
countries (Adlercreutz, Yamada, Wahala, & Watanabe, 1999; Marks et al., 2004; Miller,
1988; Parkin, Pisani, & Ferlay, 1999). The observed lower incidence rate of CaP has been
associated with higher intake of soy derived phytoestrogens (SDPs) in Asian countries
(Adlercreutz et al., 1999). Longer life expectancy and improved screening methods are
likely to increase the number of CaP cases within the global population (White et al.,
2004; White et al., 2010), and as many as 10%-15% of adult men could be affected
(Bosland, 2000; Qin, Wang, Kaneko, Hoshi, & Sato, 2003; Singh, Matanhelia, & Martin,
2008). Environmental causes have been implicated with mortality, while ethnic
differences and consumption of soy as a dietary staple have been credited for some lower
observed disease incidence (Adams, Chen, Newton, Potter, & Lampe, 2004; Hsing &
Devesa, 2001).
CaP is the most common noncutaneous cancer among males (Jemal et al., 2007;
Sharma et al., 2009). The need for available chemoprevention and other therapies has
generated tremendous interest within public health and medical communities (National
Cancer Institute [NCI], 2012). While recent reports indicate a decline in some cancers,
the incidence of CaP remains greater than 10% (American Cancer Society [ACS], 2012).
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CaP is also the second leading cause of cancer mortality among men in the USA (ACS,
2012; Centers for Disease Control and Prevention [CDC], 2012). The ACS estimated that
in the year 2012, there were approximately 241,740 new cases and 28,170 deaths from
CaP (ACS, 2012). Estimates of new cases for the year 2013 were slightly lower (238,590
new cases) with an expected mortality of 29,720 (NCI, 2013). At diagnosis, CaP
disproportionately affects African American (AA) men in both incidence and mortality
compared to Whites (ACS, 2012; CDC, 2012). Age is not alterable and is an integral
factor in the etiology of the disease (ACS, 2012; CDC, 2012). According to the CDC
(2012), AAs are 1.86 times more likely to develop CaP before the age of 65
(103.1/100,000), compared to European Americans (55.3/100,000). Similarly, AAs are
1.42 times more likely to be deceased at age 65 and older (1,137.8/100,000) compared to
European Americans (800.7/100,000).
Cancer mortality potentially continues to increase worldwide with the potential to
affect more than 13.1 million individuals by the year 2030 (WHO, 2012). Age is an
extremely significant factor in the development of all cancers. In particular a greater than
80% of CaP cases are diagnosed after 60 years of age (ACS, 2012; CDC, 2012).There is
some concern that men in Asian countries could also be affected in their older decades
despite the high level of soy intake in the diet, therefore adding urgency to this dilemma
and disease burden (Thapa & Ghosh, 2012). Improved therapies and prevention strategies
are therefore urgently needed. These strategies may help alleviate the increased disease
burden experienced among various populations. Many lives are affected and myriads of
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negative health issues accompany present therapies. More effective treatment strategies
including chemoprevention would be beneficial.
Although dietary intake of soy has increased in the U.S. over the past decades,
evidence of quantity and frequency of consumption, and the group within the population
that accounts for the highest dietary intake, remains uninvestigated. The appropriate
dietary quantity and intake duration of soy or its extracted phytonutrients in relation to
CaP chemoprevention are yet to be established. Randomized clinical trials have been
designed to qualify intervention employing soy derived phytoestrogens (SDPs), but their
examination is limited to studies which in most cases fail to yield significant and
generalizable results (Venkitaraman et al., 2008). Epidemiological research has shown
that there is 40 times greater consumption of soy in the Asian diet than consumed in the
Western diet (Sharma et al., 2009). Understanding the effect that SDPs could have
preventing CaP within the context of duration and concentration and more directly
through serum levels of PSA and estradiol (E2) following dietary intake of SDPs is
therefore prudent. Recent estimates indicate that CaP is now present among younger aged
men within the population (ACS, 2012). This earlier onset of CaP incidence among
younger aged men is further evidence of the need for novel preventive strategies or
curative therapies.
Phytoestrogens
According to Ganry (2004), Morrissey et al. (2004), and Napora et al. (2011)
SDPs, plant derived nonsteroidal compounds, are known to possess weak estrogenic
properties. Food sources rich in these compounds include legumes and soy, with the latter
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supplying an abundance of the SDPs in this study (CDC, 2012; Napora et al., 2011).
Figure 1 provides information on both natural and synthetic SDPss and the end-product
following ingestion and biochemical activity.

Figure 1. Major phytoestrogens found in soy and the influence on PSA and estradiol.
In addition to their chemoprotective properties, SDPss have the capacity to protect
the prostate gland from tumor progression, and are important as anti-inflammatory
compounds (Napora et al., 2011). SDPs are comprised of lignans, flavonoids, coumestans
and isoflavones with the latter predominantly derived from soy (CDC, 2012; Strauss et
al., 1998). Among isoflavones found in soy are genistein, glycitein and daidzein (Strauss
et al., 1998), of which genistein and daidzein are the focus of this study. Genistein’s
utilization is immediate within the body, while daidzein undergoes metabolism by
bacteria in the gut (CDC, 2012). Daidzein’s convertion to O-desmethylangolensin, then
equol and is the available estrogenic product (CDC, 2012).
There are three main types of SDPss. Broad similarity exists between estrogens,
isoflavones, and lignans, which comprise this group (BCERT, 2007). Lignans provide a
major source of the consumed SDPs in the American based diet (BCERT, 2007). They
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appear to have an inverse association with cardiovascular health (BCERT, 2007).
Cancers have also been associated with some SDPs (BCERT, 2007). The established
knowledge is that Asian based diets have a higher proportion of SDPs that correlate with
a lower CaP incidence (Hsing & Devesa, 2001). An increase in the dietary levels of SDPs
among men in the Western population could potentially provide beneficial
chemoprotection. However, while genistein and daidzein are the major isoflavones found
in soy, lignans make up the major polyphenols found in cereals, grains, some fruits, and
vegetables. However, like daidzein, these lignans undergo conversion to other
compounds by microbes found in the intestines, and newly formed compounds provide
protection from some types of disease (Hsing & Devesa, 2001).
Equol fermentation produces daidzein, while enterolactone and entereodiol are
products of fermented lignans (Linus Pauling Research Institute, 2010). Compounds
derived from lignans are possibly lacking in carcinogenic activity. However, lignan
derived compounds are considered SDPs and when converted by bacteria can exert mild
estrogenic effects (Linus Pauling Research Institute, 2010). Similar to SDPs, equol has
also demonstrated cytotoxic activity against CaP cell lines, as does its lignan derived
compound (Venkitaraman et al., 2008). Lignans exert their effect on cells including those
within the prostate. This process could result in unwanted cellular differentiation and
formation of precancerous lesions due to hypertrophy or hyperplasia (Venkitaraman et
al., 2008).
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Prostate Cancer and Phytoestrogens
The reciprocal phytoprotection associated with an increase in incidence of CaP
appears to be lacking in the US male population (CDC, 2010) and may simply be a
reflection of the minimal quantity of SDPs consumed within the Western diet. Greater
understanding of this association needs assessment. It is necessary to understand what
factors are integral to any inferred chemoprotection to be able to understand the true
effect of consumption within the target population. This encourages incorporation into
the Western diet associated CaP etiological and subsequent preemptive model. This has
resulted in the need to understand the association and to determine the exact effect size
(ES) of intervention.
CaP is considered hormonally controlled (Sekine et al., 2007; Ho, 2004).
Predominantly, female hormones, E2 and estrone are the two major estrogen hormones
secreted by the ovaries (NCI, 2012). The use of estrogens for CaP therapy has produced
some positive results; however, concerns related to increase in hormone refractory cancer
are valid. Hormonal therapy benefits include blocking of tumor growth, decrease of PSA
levels and ability to use as adjunct therapy at any time other treatment modalities. The
benefits of estrogen therapy have accompanying side effects. These side effects include
impotence, weight gain and fatigue among others. Studies have shown that the delivery
of estrogen through E2 skin patches can be effective in CaP therapy. Benefits also occur
without some of the prior mentioned side effects such as impotence and weight gain
(Strax, 2005). CaP is the most invasive tumor and ranks only behind lung cancer in
mortality incidence among men (Agarwal, 2000; Bektic et al., 2003). Treatment of CaP
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has focused on employing androgen deprivation therapy (ADT; Smith, 2007; Shahani et
al., 2008) or orchidectomy (Singh et al., 2008). Increasing therapeutic use of ADT has
been reported (Shahani et al., 2008; Singh et al., 2008; Smith, 2007). While these
intervention processes have realized some benefits, some have also resulted in the
development of unwanted events, including toxic conditions that can persist for extended
periods (Lycette et al., 2006). Mitigating these unwanted events through new therapeutic
agents including an increase in SDP intake. An increase in SDP intake is necessary, as
there is some evidence of intake in the Western diet. However, this intake remains
minimal in relation to that consumed in Asian diets.
Employing ADT, as previously indicated, has been associated with adverse health
conditions including osteoporosis, hot flashes, and changes in cognition (Basaria et al.,
2006; Cherrier et al., 2003). ADT therapy has been associated with the development of
diabetes and other health conditions, which can influence other unwanted yet serious
cardiovascular conditions (Napora, Short, Muller, et al., 2011). In fact, evidence
implicates estrogen receptors (Härkönen & Mäkelä, 2004), as favorable to the
development and progression of CaP. This conflicting report kindles the need to
understand the context of ES. It also provides an opportunity to assess the true effect of
studied SDPs in reducing or preventing CaP develo,pment or progression. Numerous
epidemiological studies and in vitro experiments have demonstrated the chemoprevention
benefits from SDPs (Kumar et al., 2011). It might therefore be plausible to assert that the
chemoprotective influence of SDPs is the ability to regulate important receptor
mechanisms. This subsequently results in a decrease in cancer development and
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incidence. In fact, research by (Bektic et al., 2003), infers that genistein has an effect on
ERβ and consequently a direct relationship on the down-regulation of those androgen
receptors. ERβ has demonstrated its influence in tumor growth and proliferation
(Härkönen & Mäkelä, 2004).
Estrogens have remained important in the treatment of androgen-dependent CaP
(Pendleton et al., 2008). The difficulty of treating CaP including hormone refractory
disease continues to influence the search for novel agents for optimum therapy
(Pendleton et al., 2008). Hormone refractory disease does not respond effectively to
presently employed drugs (Cho, Di Blasio, Rhee, & Kattan, 2003). The thought is that
greater than 20% of men who have been treated for androgen-dependent CaP will
experience disease recurrence (Cho, Di Blasio, Rhee, & Kattan, 2003). This portends
poor prognosis and decreased survivability. Present reports have indicated a greater
survival rate of CaP diagnosed individuals because of the improved treatment methods
and earlier diagnosis (ACS, 2012). Different levels of survival are reportedly associated
with tumor stage with better outcomes when diagnosed as a localized tumor with almost
100% survival (ACS, 2012). Distant metastases on the contrary are associated with
approximately 29% survival (ACS, 2012). Treating metastatic and recurrent disease is
therefore a health issue of paramount importance.
Estrogens, Estradiol and CaP
Estrogens, also known as oestrogens, are primarily female hormones. These
estrogens have important value in areas including hormone replacement therapy (CDC,
2012). They influence gene regulation because of their ability to diffuse across cell
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membranes (CDC, 2012). Hormones that occur naturally in women include estrone (E1),
estriol (E3), and 17β–estradiol (E2) with E2 observed as the predominant form (Ockrim,
Lalani, Kakkar, & Abel, 2005). Although primarily synthesized in the ovaries of women,
the discovery of estrogen receptors ER-alpha and ER-beta in the male prostate gland has
increased some evidence of its value in the development of CaP (Ockrim et al., 2005).
E2 is produced by the male reproductive system and is derived from testosterone
(Ockrim et al., 2005). The connection between its serum concentration and SDP
concentration might provide insight into the etiology of CaP. In fact, the androgen
receptor appears to be the important target during prevention and treatment (Bonkhoff &
Berges, 2008). Estrogen concentration is greatest in the male reproductive tract
(Lombardi et al., 2001) resulting in the existing correlation between androgens and CaP
proliferation (Morrissey et al., 2004). This understanding has resulted in reports
suggestive of estrogen’s role in CaP etiology including a metabolic pathway association
resulting in an associated genetic link (Bosland, 2005).
The discovery of estrogen receptors, including possibly close correlation between
a specific genetic polymorphism on ER-α and its link to the development of CaP,
demonstrates a close relationship between estrogen and CaP (Bonkhoff & Berges, 2008;
Bosland, 2005). In addition, the relationship between ER-β and CaP development is
expressed through its down regulation in more malignant disease (Bosland, 2005) and
during the progression of hormone-refractory disease (Bonkhoff & Berges, 2008). In
addition, this ER-β relationship is observed in normal prostate tissue, benign prostatic
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hyperplasia (BPH), and CaP, providing an opportunity for chemoprevention (Bonkhoff &
Berges, 2008).
Risk of Developing CaP
While some cancers have experienced decline over the past decades, CaP
continues to show an increase in incidence (NCI, 2012). In 2011, US estimates of CaP
were approximately 241,740 new cases, with an expected mortality of 28,170 (NCI,
2012). Those numbers are representative of the upsurge in CaP incidence from 2007
when 223,307 cases were diagnosed in the US (CDC, 2012). However, compared to the
estimated number of new cancer deaths that would occur based on 2007 data, the actual
number of deaths (28,170) represent a slight decrease from 29,093 cases (CDC, 2012). A
decrease in mortality from cancer is associated with an increase in early detection.
As mentioned earlier, the risk of developing cancer increases with age. Figure 2
illustrates the percent of U.S. men who developed CaP over various decades starting at
age 30 through 70. At age 30, men have a relatively low risk of developing CaP with
0.01% by the time they reach age 40, 0.32% at age 50 and 2.49% at age 60. However, the
percentage of men currently age 40 and older who will develop CaP after 30 years
increases proportionately to 8.30% of men by age 40, 14.40% by age 50, and 16.11% by
age 60. At age 70, men have the same risk (8.50%) of developing CaP after 10 years than
men currently aged 40 after 30 years.
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Figure 2. Likelihood (%) of Developing CaP Over 3 Decades Based on Current Age,
2005–2007. Source: Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R,
Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis
DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds). SEER Cancer
Statistics Review, 1975–2007, National Cancer Institute. Bethesda, MD, based on
November 2009 SEER data.
Problem Statement
The disease burden of CaP among Western men is significantly greater than that
observed among men in Asia, where soy is a dietary staple. While there has been
extensive epidemiological research evidence supportive of the anticancer value of soy
compounds among the Asian population, recent inclusion of SDPs in Western diet has
not yet shown a noticeable reduction in disease incidence and outcome. Epidemiological
evidence indicates soy based diets containing SDPs provide valuable chemoprotection.
The threshold level of concentration and duration of soy based dietary intake contributing
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to chemoprotection represents invaluable knowledge. Intake duration and concentration
could help address the risk of CaP among high risk minority and other populations. This
study addresses the problem of recurrence and identification of potential failure for any
successful therapeutic intervention. Potentially, this research will provide evidence for
further studies that could decrease CaP incidence and influence broad social change
through improved health status and overall quality of life (QOL).
Purpose of the Study
The purpose of this study was to determine the ES of serum PSA and E2 levels
following dietary genistein and diadzein intervention. Serum levels of PSA and E2 are
important predictors of therapeutic response and disease outcome. Studying the response
of PSA and E2 in American men and disease outcome has not previously occurred in that
cohort. Guided by the principles of primary and secondary prevention and an original
model of cancer prevention, the dual prevention intervention model, the study sought to
answer whether intake duration and concentration of SDPs directly influence magnitude
and direction of CaP response. Information for analysis in this study came from selected
published randomized controlled trials (RCTs) of SDP intervention designed to prevent
or delay recently diagnosed CaP, increasing PSA and hormone refractory CaP in men
between 50–85 years old.
Theoretical Base: Dual Prevention Intervention Model
The theoretical base for this study has roots in one of the recognized multistep
models of development of neoplasia or tissue growth arising from the biological sciences.
The putative multistep pathway model (Giovannucci, 1999) provides evidence for the
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indication of chemoprevention through SDPs. Giovanucci’s model was structured on the
premise that intake levels of SDPs are associated with the lower incidence of CaP
observed among men in Asian countries. CaP carcinogenesis through the presence of
increasing PSA is one of the mechanisms depicted in this model as early evidence of
damage to the normal prostate tissue resulting from genetic mutation and cellular
damage. Biological models do not focus on the principles of primary cancer prevention
and control and the approach to disease prevention has unfortunately reflected this
premise in that screening for CaP is a secondary prevention effort aimed at detecting
increasing PSA. At the same no new biomarkers to detect changes in the normal prostate
tissue have been discovered or suitable for use at a population level.
The strategy of the dual prevention intervention model (DPIM) is to present an
original contribution to the field of public health that aims to avert early prostate tissue
damage (Michelin & Gutierrez, 2013). Figure 3 depicts the premise of the DPIM
conceptual model, which posits that the development of CaP and other cancers result
from continued interaction to environmental and biological exposures. Over time, these
exposures result in cellular changes from stress and resulting mutations that may occur
with prolongued exposure. Beyond the multistep causative mechanisms, the DPIM has
identified critical points at which a public health primary prevention approach through
phytochemical intervention and a potential therapeutic intervention through secondary
prevention can be implemented in high risk populations such as African Americans. The
primary prevention component of the DPIM recognizes that other theoretical models
proposed in the literature focus on the identification of mitigating factors that result in
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cellular biological changes. These activities lead to the development and progression of
CaP. Preventing or delaying cellular biological changes that result in CaP development
and progression is the focus of the DPIM.
The goal of this research is to prevent, delay, or reverse disease through dietary or
medicinal addition of SDPs to avert development and progression of prostate tumor.
Mitigating factors such as age, inflammation, change in hormonal status and genetic
mutations is of valuable importance to this process. While several studies have provided
scientific support for events that describe such association (Wang, Clubbs, & Bomser,
2006), the true ES of SDP intervention on individuals at various stage, grade or type of
CaP has not been completely analyzed and presented in the present literature. While the
model by (Giovannucci, 1999) provided for later androgen deprivation therapy (ADT)
and other chemotherapeutic agents for treatment, the DPIM focuses on the identification
of a critical point for primary prevention intervention. The broader scope of the DPIM is
shown through this meta-analysis that showed the true ES of SDP intervention. The
research revealed the much desired importance of secondary prevention using SDPs
inclusive of E2 therapy. The study result showed that decrease in serum PSA
concentration was a desired outcome from SDP intervention.
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Exposures:
Environmental,
Biological,
Genetic &
Internal
stressors

Phytoestrogen: 1o
Preventive
Intervention

Healthy
Prostate
Tissue

Synthetic hormones: LH blockers, GnRH blockers,
Anti androgens. Side effects include impotence,
osteoporosis, depression, memory problems. Increased
dosage of SDPs

Progression/
Delayed PIN
Development
Hormonal
imbalances

Advanced PIN Development
Decrease in Serum estradiol
Rising/Stabilized Serum PSA
Change in other hormones
(testosterone)

Estradiol Therapy:
2o Preventive Intervention
SDPs including
Genistein/Daidzein
/chemotherapy
Absence of Intervention

Combination Therapy for
Advanced/Recurrent CaP
without increasing
Serum PSA

Prostate
Cancer

Surgery
Brachytherapy
Radiation
Other therapies

Figure 3. Dual Prevention Intervention Model (DPIM). Michelin & Gutierrez, 2013, n.p.
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Nature of the Study
The study was a quantitative analysis of data from published randomizedcontrolled trials (RCTs) demonstrating the chemoprevention ability of soy and its derived
SDPs. The population sampled included men ages 50-85 in the United States. The studies
were analyzed employing meta-analysis. The independent variables were dietary
quantities of the SDPs genistein and daidzein. The dependent variables included serum
levels of E2 and PSA. I sought to determine the ES in SDP dose-response intervention in
selected male populations during the therapeutic application for recently diagnosed and
recurrent CaP, and the contribution of duration and concentration in determining the size
and direction of action. The principles of primary and secondary prevention and the
original conceptualization of the DPIM of cancer prevention guided this research study. I
sought to answer whether intake duration and concentration of SDPs directly influence
magnitude and direction of serum PSA and E2 during various conditions of CaP disease.
I conducted a statistical analysis employing CMA specialized software to determine the
ES using Odds Ratio statistic and the REM. Odds Ratios were calculated through 2x2
contingency tables. Confirmatory analysis included Cohen’s d, Q statistic, and mean
standardized differences. Heterogeneity was measured using g statistic. (More details
provided in Chapter 3).
Research Questions and Hypotheses
The ingestion, duration, and concentration of SDPs are responsible for the
associated lower incidence of CaP and other prostate diseases observed among Asian
males (Dalais et al., 2004). Inversely, its decreased intake among men in Western
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countries appears to be associated with a higher incidence of CaP and other prostate
diseases. Answering the research questions provided some perspective on the effects of
different independent variables on dependent variables and subsequently on disease
outcome among men in Western countries. I sought to answer the following questions:
Research Question 1: Is there a correlation between dietary SDPs and serum SDP levels?
Null Hypothesis H1o: There is no correlation between dietary SDP levels and
serum SDP levels.
Alternative Hypothesis H1A: There is a correlation between dietary SDP levels
and serum SDP levels.
Research Question 2: Is there a correlation between dietary SDP levels and serum PSA
levels?
Null Hypothesis H2o: There is no correlation between dietary SDP levels and
serum PSA levels.
Alternative Hypothesis H2A: There is a correlation between dietary SDP levels
and serum PSA levels.
Research Question 3: Is there a correlation between dietary SDP levels and serum E2
levels?
Null Hypothesis H3o: There is no correlation between dietary SDP levels and
serum E2 levels.
Alternative Hypothesis H3A: There is a correlation between dietary SDP levels
and serum E2 levels.
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Research Question 4: Is there a correlation between serum SDP levels and serum PSA
and serum E2 levels?
Null Hypothesis H40: There is no correlation between serum SDP levels and
serum PSA levels.
Alternative Hypothesis H4A: There is a correlation between serum SDP levels and
serum PSA levels.
Research Question 5: Is there a correlation between serum SDP levels and serum
E2 levels?
Null HypothesisH5o: There is no correlation between serum SDP levels and serum
etradiol levels.
Alternative HypothesisH5A: There is a correlation between serum SDP levels and
serum E2 levels.
Definition of Terms
Androgen deprivation therapy (ADT): Treatment that is used to block or suppress
the production or action of the male hormones known as androgens. This is achieved by
either removal of the male testicles, or blockage with female hormones or drugs called
antiandrogens. This type of therapy is also referred to as androgen ablation or androgen
suppression (NCI, 2012).
Benign prostatic hyperplasia/Benign Prostatic Hypertrophy (BPH): A noncancerous condition which involves an excess growth of prostate tissue that pushes
against the urethra and the bladder resulting in a blocking of normal urine flow (NCI,
2012).
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Cancer recurrence: Cancer which has returned after a period of time in which the
cancer was unable to be detected. This cancer might return to the same place as the
previous tumor but could also return to a different region of the body (NCI, 2012).
Chemopreventive: The use of drugs, vitamins, and other compounds to try and
reduce the risk of development, recurrence or progression of cancer (NCI, 2012).
Chemoprotective: The quality displayed by some drugs used for treating cancer.
The chemoprotective agent protects the healthy tissue from the toxic effects of drugs used
during cancer therapy (NCI, 2012).
Chemotherapy: The killing of cancer cells using drugs (NCI, 2012).
Diagnosis: “the process responsible for identification of a disease such as cancer
from its sign and symptoms” (NCI, 2012).
Daidzein: An isoflavone fond as a biochemical component of soy (NCI, 2012).
Disease incidence: The number of new cancer cases over a specific period of time
which is usually recognized as one year.
Distant metastasis: This is a reference to cancer that has spread from the primary
tumor to distant organs or lymph nodes. Also related to as distant cancer.
Digital Rectal Examination (DRE): A procedure in which a trained medical
practitioner performs a digital examination of the prostate employing appropriate and
established medical practice (NCI, 2012).
Double-blind: A clinical trial in which the medical staff, the patient, and the
people who analyze, the results, do not know the specific type of treatment the patient
receives until the trial has been completed (NCI, 2012).
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Isoflavones: Nonsteroidal plant derived phytoestrogen compounds which can bind
the estrogenic receptors and can affect the normal estrogen regulation process (NCI,
2012).
Effect size: This is considered a numerical way of assessing the strength or
magnitude of a reported relationship even it is seen as casual or otherwise (Villanova
University, 1984).
Epidemiology: According to the WHO (2012), epidemiology is the study of the
distribution and determinants of health-related states or events which includes diseases
and the use of epidemiological practices to control these diseases and other health
conditions.
Estrogens: Any of several major female sex hormones produced primarily by the
ovarian follicles of female mammals, and capable of inducing estrus (oestrus),
developing and maintaining secondary female sex characteristics, and preparing the
uterus for reception of a fertilized egg. It is used especially in the synthetic form as a
component of oral contraceptives in certain treatments and other forms of therapy (NCI,
2012).
Etiology: “the origin or cause of disease” (NCI, 2012).
Fixed Effects: The assumption that there is only one true effect size
(Wiley/ITMA, 2009).
Genistein: An isoflavone found as a biochemical component of soy (NCI, 2012).
Gleason Score: According to the (NCI, 2012), Gleason score is the system
presently employed to grade CaP tissue in context to how it appears when viewed
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microscopically. The Gleason score ranges from 2 through 10 and is a reflection of the
likeliness of the tumor spreading to adjacent tissues. Lower Gleason score indicates a
decreased likelihood of the tumor spreading while a higher Gleason score is indicative of
tumor with greater likelihood of spreading. It also demonstrates a higher variability from
normal prostate tissue.
Hormone Refractory Disease/Hormone Resistant Disease (HRD): A disease
condition that does not respond to hormone therapy (NCI, 2012).
Morbidity: Relates to a disease or incidence of disease within a population. It also
refers to the adverse effects resulting from a treatment (NCI, 2012).
Mortality: A reference to the death rate which is also the number of deaths in a
particular group over a specific period of time. Mortality might also be reported for
people with a particular disease, live in one area of the country, and who belong to a
certain age, gender, and ethnicity (NCI, 2012).
Outcome: “an effect that is measurable or a specific result. Examples of outcomes
include decreased pain, reduced tumor size, and the improvement of disease” (NCI,
2012).
Phytoestrogens: Morrissey et al. (2004) indicated that phytoestrogens are
considered nonsteroidal compounds derived from plant sources and which have
estrogenic activity.
Prognosis: This is the likely outcome or course of a disease but can also be
defined as the chance of recovery from a disease or recurrence of the disease (NCI,
2012).
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Prostate Specific Antigen (PSA): A protein substance that is produced by the
prostate gland and when found in the blood at a higher level than considered normal
might be an indication of CaP, BPH, inflammation or infection (NCI, 2012).
Prostatic Intraepethelial Neoplasia (PIN): Noncancerous growth of the cells
lining the internal and external surfaces of the prostate gland. Having high-grade prostatic
intraepithelial neoplasia may increase the risk of developing CaP. (NCI, 2012).
Prostatitis: Considered inflammation of the prostate gland (NCI, 2012).
Radical prostatectomy: A surgical procedure that removes all of the prostate
gland and some of the surrounding tissues (NCI, 2012).
Radiotherapy: Also called irradiation or radiation therapy. Involves the use of
various high-energy radiation sources including x-rays, gamma rays, neutrons, protons
and other sources to destroy cancerous cells and shrink tumor. Radiation can be from an
internal source placed near the cancer cells or from an external source where beams were
directed against the cancer cells. In systemic radiotherapy, the source is radiolabeled
monoclonal antibodies that reach tissues after traveling through the blood (NCI, 2012).
Random Effects: The assumption that the true effect could vary from one study to
the next (Wiley/ITMA, 2009).
Randomized Clinical Trial: A study in which the participants are assigned by
chance to separate groups that compare different treatments; neither the researchers nor
the participants can choose which group. Using chance to assign people to groups’ means
that the groups will be similar and that the treatments they receive can be compared

23
objectively. At the time of the trial, it is not known which treatment is best. It is the
patient's choice to be in a randomized trial (NCI, 2012).
Receptors: Structure on cell surface or inside cell that selectively receives and
binds a specific substance (MedicineNet, Inc., 2012).
TRAMP mice: Transgenic adenocarcinoma of the mouse prostate (Hurwitz,
Foster, Allison, Greenberg, & Kwon, 2001).
Assumptions
This study is based on several major assumptions. The first assumption is that the
lower incidence of CaP observed among Asian men is attributable to the greater intake of
dietary soy derived SDPs/isoflavones namely genistein and daidzein (Willis & Wians,
2003). The second assumption implies that the resulting metabolic changes from SDP
intake produce bioactive compounds linked to this lower incidence of prostate diseases
observed within the Asian male population (Bektic et al., 2005; Kumar et al., 2011). The
third assumption was that that an increase intake of soy derived dietary isoflavones
among men in Western countries would result in a decrease in CaP incidence. The fourth
assumption was that the beneficial changes in CaP are associated with serum, a decrease
in serum PSA level, and an increase in serum E2 level. The fifth assumption was that a
reduction in disease incidence would result in beneficial health outcomes within the
western male population and reduce the disease and economic burden associated with
disease treatment and management. The sixth assumption was a reduction or elimination
of potentially unnecessary screenings, treatment, and a reduction of valuable quality of
life issues that are associated with care and management of the disease. The seventh
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assumption was that the employment of meta-analysis will mitigate differences in and
between studies and provide statistical relevant ES information. The eighth assumption is
that if findings demonstrate a positive correlation to E2 and inverse relationship to PSA
response then further exploration of therapeutic or chemoprevention explored for other
hormonal driven cancers including breast and ovarian cancers. The ninth assumption was
that the variables had the potential to influence the outcomes and subsequent data
presented in the analysis. Finally, evidence from this meta-analysis examination used to
establish recommended daily dietary value for these studied SDPs.
Limitations
The following limitations were anticipated. This meta-analysis used data of prior
research from selected published RCTs. These output data included the use of already
established methods of data collection. The strategies employed in those prior analyses
and the evidence presented from those studies is not amenable. These data are an
accumulation of output data from other studies that included subjects who are different
demographically, in age, in ethnicity, and socioeconomic status, possibly with numerous
different health backgrounds. There is also the issue of reliability of the information
source since it is difficult to monitor if diets consumed consisted of the soy products that
are associated with the studied chemo-protective activity. Limitations also included the
inability of the researcher to define criteria for selection as these were already determined
by the RCT process. An important limitation relates to the coding, or data extrapolation
process, as this process requires proper monitoring to ensure correct information
retrieval, then the effect size values regarding the treatment outcomes would be incorrect.
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Another limitations might also be present in the selection process used to recruit subjects
for the different studies. Several conditions including age, health history and weight of
participants were possibly important confounders and therefore, could have a negative
influence on the produced output data.
Delimitations
The following were delimitations in this study. The role of environmental,
genetics, and other exposure factors can be important delimiting factors. Factors
contributing to the initial onset of prostate disease are observed through prostate
intraepithelial neoplasia (PIN) development following extensive exposure. Delimitations
might also be evident in the method of analysis been employed to determine the true
effect of duration on the chemo preventive role of SDPs.
Significance of the Study
The dynamics of the interaction between phytoetsrogens, tumor development,
proliferation, prevention, and even recurrence are valuable to greater understanding of
implementation of workable intervention strategies. It is through understanding of the ES
from research evidence that strategies can be developed, novel therapies implemented
and, further research pursued that could help improve health outcomes. Information
might also be important in its role of decreasing CaP disease incidence in populations that
are considered at greater disease risk. There is not only an economic burden but also the
social and psychological experiences of those affected by CaP (Turner et al., 2009). An
event that can reduce the impact of social and other burden on the individual, the family
and the wider supportive family of social network, would be valuable. Therefore,
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addressing issues of quality of life (QOL), physical and mental strain, and improving the
broader outlook associated with survivability and improved health outcomes (Sharpley,
Bitsika, & Christie, 2011; Turner et al., 2009). Understanding how CaP impacts those
affected and those in the broader community through greater awareness are also
important concepts that the study addressed. With CaP considered a disease that will
increase as the male population gets older and there is a greater possibility, of the
incidence of CaP, than any intervention that could reduce such incidence including the
tremendous economic and health burden that is associated would be of tremendous social
value. In the social context, there would also be a greater desire to have soy products
become a dietary staple. This could change the present outlook of the disease within the
more at-risk communities and importantly among the populations now experiencing
higher incidence.
This study is significant in that it presents an original contribution to the field of
public health that aims to avert early prostate tissue damage through identification of a
critical point at which a primary prevention is incorporated. The goal of this research and
the DPIM (Michelin & Gutierrez, 2013) is to prevent, delay, or reverse disease through
addition of SDPs either dietary or medicinally to avert progressive development of
prostate tumor. While several studies had provided scientific support for the events
describing such association, in this study, I analyzed relevant literature and determined
the true ES of SDP intervention on individuals with various stage, grade or type of CaP.
Through the broader scope of the DPIM, the meta-analysis of the true ES revealed the
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much more important secondary preventive role of SDPs through E2 therapy compared to
expected decreases in PSA as the desired outcome.
Summary and Transition
Chapter 1 provided an overview of CaP in the US population. There is need for
examination of the shortfalls regarding the present therapeutic practices. How these
reflect the need for novel therapies for improved health outcomes. Some relevant
discourse is presented based on the studies employed in this meta-analysis and how this
present a worthy context to the research focus regarding the employment of various soybased products for CaP therapy or prevention. This is important not only in context to
complementary and adjuvant therapy but as the defining therapeutic intervention process.
Chapter 2 will be devoted to the review of supportive literature that will offer scientific
insight and knowledge base. This information will span a vast array of material
incorporating theoretical and experimental discourse and providing even greater
understanding and relevance to the various aspects of the disease process. The study
discusses potential benefits of SDPs for therapeutic intervention in combating the
incidence of CaP. Chapter 3 is a detailed presentation of the research methodology which
relates to ES, and importantly how this is demonstrated employing either an open- or
fixed-effect model analysis. However, in this study, I used the REM for ES analysis.
REM represents a more precise evaluation of the aim and objectives of this study. The
assumptions will support or offer a clear relationship between SDPs and their value in
helping to reduce CaP. The debilitating effects of CaP remain in ethnic populations still
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affected by higher disease incidence. These populations continue to experience greater
disease burden than the male population in Asian countries.
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Chapter 2: Literature Review
Overview
The purpose of this study was to determine through OR meta-analysis the ES of
genistein and daidzein on PSA and E2 serum levels. The magnitude and direction of that
response to dietary and then serum genistein and daidzein levels will also be determined.
The influence on both PSA and E2 serum levels could be valuable in determining
treatment outcomes in diagnosed CaP cases, rising PSA, and HRCaP. The effect of
dietary and serum SDPs on PSA and E2 serum levels has not previously undergone
analysis in this cohort of American men. The chapter has several sections. These include
the literature search strategy, background of prostate and hormone refractory cancer,
epidemiology and pathophysiology of CaP, theoretical base and theoretical applications
of CaP and SDPs, E2, and PSA. Literature on differing views and methodology related to
RCTs involving chemoprevention intervention is also included. There is also a
concluding summary of the chapter and transition to Chapter 3.
Literature Search Strategy
Conducting a review of pertinent literature involved extensive search of Science
Direct, SciVerse, PubMed, and Walden University’s online library. Search terms used
included phytoestrogens and cancer therapy, phytoestrogens and prostate cancer,
genistein and cancer therapy, and several combinations of terms that included either
prostate cancer, genistein, daidzein, and/ or phytoestrogens. The articles selected for
analysis in this study were selected following a search of Science Direct, SciVerse and
PubMed using a collection of terms that included phytoestrogens and prostate cancer
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therapy. The selected studies also had to include the terms of randomized-controlled
double-blinded clinical trials, which employed either genistein and/or daidzein as
included elements of the study process.
Prostate and Hormone Refractory Cancer
CaP including HRCaP (Crawford, 1992; Sadar, Hussain, & Bruchovsky, 1999)
follows surgical castration or disease not responding to androgen deprivation therapy
(ADT; Napora, et al., 2011; Sharifi, Gulley, & Dahut, 2005). It accounts for over 10% of
cancer cases, and is expected to fail all present therapies. The subsequent recurrence is
associated with poor health outcomes as a consequence of this difficulty to treat the
resulting disease (Singh, Matanhelia, & Martin, 2008).
While results might be somewhat unpredictable, evidence suggests that use of
secondary hormonal therapy could provide some health benefit (Pendleton et al., 2008;
Ryan & Small, 2003). This perspective can be relevant when appreciating the dietary
intake of SDPs. Intake of SDP is estimated to be 60 times greater within the Asian
population than among Western men (Qin et al., 2003; White et al., 2004). Several
researchers, including Adams et al. (2004), Boyle, Maisonneuve, and Napalkov, (1995),
and Hsing and Devesa, (2001), have also acknowledged that there are health benefits that
can be attributed to the intake of SDPs. These include a difference in the incidence of
prostate diaseases observed among Asian men who have immigrated to Wetsern
countries (Adams et al., 2004; Boyle, Maisonneuve, & Napalkov, 1995; and Hsing &
Devesa, 2001). Some context to potential health benefits of SDPs also relates to the
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observations made regarding the detection of isoflavones in the serum of newly born
babies (Adlercreutz, Yamada, Wahala, & Watanabe, 1999).
This implied evidence of chemoprotection provides the opportunity for
complementary and alternative modalities (CAM) to be implemented as intervention or
proposed treatment strategies (White et al., 2004). The inclusion of SDPs and other SDPs
into the Western diet has not seen similar lowering of CaP incidence. This observation
suggests that CaP and other prostate diseases are still been defined by a higher incidence
rate among Western men. Globally, the most prevalent cancers include prostate, lung,
colorectal, stomach, and breast cancer (WHO, 2012). Significantly, in regions surveyed
by the WHO, the report implies that the highest incidence occurs in Europe and the
Americas (WHO, 2012). However, the lowest observed incidence is in Southeast Asian
countries where SDPs are an important dietary staple (WHO, 2012).
Hormonally influenced cancers include CaP, ovarian, and breast cancers. These
cancers affect millions globally. The concerns regarding response to present therapies
have resulted in the need for complementary modalities such as herbal and enzyme
therapies, hydrotherapy, and the use of soy-derived components including the isoflavones
genistein and daidzein (Auerbach, 2006). These have shown the potential to elicit
positive therapeutic response (Auerbach, 2006). The lack of information regarding the
etiology of HRCaP from initially-treated cancer that had responded to therapy, has also
been demonstrated through in vitro analysis and expression of the androgen receptor
Ki67, receptor BCAR and decreased staining of 5α-reductase, aromatase and estrogen
receptor β (Celhay, Yacoub, Irani, et al., 2010). Evidence suggested that during relapse
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there appeared to be a lower expression of estrogen receptor α which was also inversely
proportional to the proliferation of tumor cells (Celhay, Yacoub, Irani, et al., 2010).
Therefore, progression from a disease that initially responded to hormone therapy and
subsequently fails to respond presents an important point regarding the issue of
recurrence and tumor progression (Celhay, Yacoub, Irani, et al., 2010).
The concern of finding an appropriate model for research is also still an issue.
Hypothetical models such as the oxidative stress model by Thapa and Ghosh (2006), and
the putative multistep model by Giovannucci (1999), which is the model followed by this
research, provide some context to the development of the disease and opportunity for
therapy and chemoprevention. However, the benefit of the mammalian model is tied to
the relationship between species and is suggestive of some parallels in the etiology of the
disease. Certain phases of the mammalian model have shortfalls, which underscores the
complex development and progression associated with CaP. Antioxidants are found
predominantly in fruits and vegetables and also viewed as important anticancer agents.
This antioxidant involvement in reducing the inflammatory process is among the
important benefits and anticancer activity of soy derived SDPs (Borek, 2005).
These sections provide an attempt to understand these associations with CaP
etiology and how these complex events can be understood within the context of SDP
intervention. Understanding the complex CaP models that provide additional background
regarding the multifaceted development of the disease and including the significant role
of estrogen in its etiology is also valuable. Problems relating to disease recurrence
following ADT and surgical castration provide some insight into the complex
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management problems. Poor outcomes appeared to be associated with a decreased
expression of the estrogen receptor ∞ and what is considered high proliferation index
(Celhay, Yacoub, Irani, et al., 2010). With CaP considered a disease, where the risk
factor and incidence increases with age, then understanding the value of SDPs as a
preventive or curative option, will be important. In fact, there appears to be some
credence afforded to this thought, with the evidence suggesting that men who had
developed a westernized lifestyle following migration and included lifestyle changes
subsequently also had an increased risk of CaP development (Haenszel & Kurihara,
1968; Staszewski & Haenszel, 1965; Wang, Clubbs, & Bomser, 2006).
Evidence presented through findings from in vitro studies (Wang, Clubbs, &
Bomser, 2006), also indicates the important role of genistein in the signal regulation of
estrogen. Genistein is one of the isoflavones that is of interest to this study. Human
studies have also demonstrated the chemoprotective value of SDPs with focus placed on
the soy derived isoflavones genistein and diadzein that are soy derived. The effect of
these compounds in alleviating the disease burden in the population is a focus of this
dissertation and will be analyzed employing meta-analysis of data from representative
selected randomized trials that will reveal the true ES of these SDPs on CaP within the
population. The result of either being preventative or curative in relation to CaP will be
defined following analysis of intake duration. This will demonstrate their ability to
significantly assist in reducing the present burden in prostate disease now experienced
among males in Western countries when compared to that experienced among males in
Asian countries.
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Epidemiological data appear to indicate the presence of SDPs in neonates
following birth from mothers known to have consumed high quantities of SDP in the
diets (Adlercreutz, Yamada, Wahala, & Watanabe, 1998). Presentation has been made on
the available understood natural history of CaP, including the screening methods and
subsequent tests that are employed in establishing a positive diagnosis. Present theories
that have been established in relation to hormone refractory disease, the success and
failure of presently available drugs for disease treatment, and the continuing trend of
employing SDPs, and significantly those associated with soy products which have
experienced a continuing upsurge in use over the past decades.
CDC (2012) data indicate a trend that acknowledges a statistical decrease in
disease incidence within the US population. However, trends appear to be different from
those provided by the World Health Organization (WHO). Reports indicate an increase in
cancers and globally cancer related mortality is predominantly from five cancers
including CaP (WHO, 2012). However, while significant decrease in cancer incidence is
represented by a total 1.6% among the US population, data indicate only minimal
reduction in CaP (CDC, 2012). Disproportionately, the incidence rates remain higher
among minority populations, and African American men record the lowest annual
decrease of 1.7% between the years 1998 to 2008 (CDC, 2012). There is need to
appreciate the value of these WHO supported reports. WHO (2012) also detailed the
significance of CaP in various geographical regions, with greater incidence in the
developed economies (WHO, 2012).
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Improved medical therapies and improved diagnostic tools have not resulted in a
significant decrease in incidence among CaP and other prostate maladies experienced by
men in Western countries. Evidence from several epidemiological studies have also
shown an increase in CaP cases among men in Western countries with annual incidence
and mortality rates greater than 200,000 and over 20,000 respectively (Jemal et al., 2009;
White et al., 2010). Hormones are known to influence the growth and proliferation of
prostate tumor cells (Bonkhoff & Berges, 2009; Harkonen & Makela, 2004; Lombardi et
al., 2001; Qin et al., 2003; Singh et al., 2008; Weihua et al., 2002). However, hormone
independent CaP accounts for a vast number of disease recurrences, even in men who
have undergone radical prostatectomy/surgical castration (Chang, Cheng, Huang et al.,
2009). There is also evidence that PSA levels can rise independent of prostate disease
(Ito, Yamamoto, Ohi, et al., 2003), which can also complicate any true dependence on
PSA levels as a reliable indicator of either disease progression or limitation.
This disease is not only difficult to treat, but does not respond to several of the
present therapeutic agents and is marked by poor prognosis and disease outcomes. A
beneficial role of dietary SDPs has been proposed for hormonally dependent diseases
(Strauss et al., 1998). The work by Hamilton-Reeves, Rebello, Thomas, Slaton, and
Kurzer (2007) implies that intake and duration of soy components possesses protective
capability for men with high risk of developing CaP. This protection was due to a
lowering of serum hormones including E2 from ingested soy proteins and therefore seen
as beneficial to the deterrence of CaP (Hamilton-Reeves et al., 2007), probably through
estrogenic and antiestrogenic effects, and enzymatic and other nonhormonal factors
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considered important to the actions (Strauss et al., 1998). In Asian men where soy based
diet is a staple, there appears to be a lower incidence of CaP and various prostate
diseases. Understanding the strength of the association between SDPs and preventing
CaP is important to initiating a prevention program.
Previous in vitro work by Fotsis et al. (1995), Onozawa et al. (1998), and Shao et
al. (1998) has demonstrated the PSA lowering ability of this SDP. A study by (Sharma et
al., 2009) also appeared to corroborate phytoprotective ability through improved quality
of life (QOL) indicators for cognitive and erectile dysfunction issues. Others were not
improved in androgen deprivation therapy (ADT) treated subjects (Sharma et al., 2009).
The (ACS, 2012; CDC, 2012) implied that these problems can be attributed, to the
extensive utilization and quite often, unnecessary use of medical treatment for prostate
diseases. There is also significant disease recurrence following radical prostatectomy,
hormone treatment, radiotherapy, chemotherapy and other adjuvant therapies (ACS,
2012; CDC, 2012). Importantly, and certainly invaluable to the foundation of this study is
the fact that epidemiological evidence points to no distinguishable tumor present in male
chimpanzees that primarily consumed plant based diet containing lignans and SDPs
(Fuhrman, 2012; Musey et al., 1995). These compounds are attributed to the almost
nonexistent cancer incidence and burden in these mammals (Fuhrman, 2012; Musey et
al., 1995). While early diagnosis offers tremendous opportunity for effective treatment
and ≥ 99% survival, the lack of a reliable therapy and a method for early diagnosis,
presents some concern. The slow growth of some tumors also allow for what is
considered surveillance or watchful waiting (WebMD, 2012). A scheduled surveillance
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allows for implementation of the most suitable therapy (WebMD, 2012). In fact,
uncertainty remains regarding the appropriate time for androgen therapy, and concerns
regarding associated side effects from testosterone suppression include osteoporosis and
reduced QOL (Vaishampayan et al., 2007). QOL certainly becomes a major issue during
CaP therapy. In fact, individuals who are diagnosed with metastatic disease where
survival is highly reduced remain a group that needs access to more effective therapy.
Treatment should be geared to increasing survival and improving QOL. There is also
need to understand the antioxidant capacity SDPs (DiSilvestro et al., 2006), though there
is already established support of antioxidant relationship to cancer prevention (Borek,
2005; Collins, 2005; Czernichow, Thapa & Ghosh, 2012; Galan, & Hercberg, 2005
Jayaprakash & Marshall, 2011). Earlier prevention could avert more complicated
progressive disease conditions.
Reliability and sensitivity concerns also plague the PSA test, which is still
employed as a primary diagnostic tool (ACS, 2012; CDC, 2012). The test is also
important in the follow-up process for disease response during therapy, and as the
precursor process to the digital rectal examination (DRE) and other diagnostic tools
(ACS, 2012; CDC, 2012). Consequently, a reduction in PSA level in response to SDP
intake, while valuable for disease response, can demonstrate even more value if the
statistical analysis corroborate and complement survival and better health outcomes. The
association between SDP intake and decreased PSA is also important in future analysis
regarding lower incidence rate in those high-risk populations. Also important is
recognition that the reliability and specificity of the PSA test still seem inadequate, since
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the present cut-off value of 4ng/ml can be unreliable in confirming CaP. Lowering the
value to 2.5/3.0 ng/ml, especially in younger males has therefore, been proposed
(WebMD, 2012). Some beneficial association is evident regarding the influence of SDPs
on PSA during less advanced disease, although demonstrating diminishing correlation
(White et al., 2010).
Another concern relates to prostate diseases affecting younger men and not only
men in the later decades, where mortality might be attributable to other diseases (CDC,
2012). Again, the need for more reliable therapeutic and preventative interventions
should therefore be paramount. Disease recurrence is also anticipated among five percent
of all those affected by CaP (ACS, 2012). With age considered possibly the greatest risk
factor, prevention is certainly a prudent strategy.
BPH, introduced earlier, does not necessarily imply progression of CaP. However,
an association has been established and, prevention of BPH through SDP intake might
significantly reduce this problem including the potential for further disease initiation
(Lee, Gomez, Chang, et al., 2003). Both BPH and CaP have been acknowledged as
having lower incidence among Asian men, among whom ADPs is a dietary staple. It is
this protective role that appears to be important in the lower incidence of prostate
diseases such as BPH and CaP among Asian men. It is important to determine the
consumption practices of those products that can benefit the health of men in Western
countries.
CaP risk is still evident even after orchiectomy or androgen ablation to surgically
inoperable cancer as development of resistance usually occurs within months or a few
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years (Singh et al., 2008). This development of androgen-insensitive tumors usually has
poor prognosis and decreased survivability (Singh et al., 2008). CaP is a very complex
disease and management with the aim of effecting long term curative outcome, is still a
very difficult situation. There is still uncertainty about the etiology of CaP although
evidence points to continuous mutation of abnormal cells that subsequently proliferates
and metastasizes (Mayo Clinic, 2011). The potential for SDPs in a preventative context
therefore, appears quite prudent. Information from several randomized-controlled studies
implies further benefits through the reduction of PSA than other biochemical responses.
Estrogen therapy remains widely employed and continues to be associated with concerns,
including possible involvement in influencing CaP growth and proliferation (Bonkhoff &
Berges, 2009; Celhay et al., 2010). SDPs therefore, appear to be multifaceted in their
ability to provide chemoprotection to prostate gland cells (Guy et al., 2012; Hsing, Tsao,
& Devesa, 2000). The added biochemical characteristics of SDPs as an antioxidant might
certainly be important in the displayed chemoprotective ability (Borek, 2005). Among
biological concepts that have been studied are modifications on the androgen receptor
(AR) gene through mutation or amplifying activities, and phosphorylation of AR protein
(Celhay et al., 2010).
Epidemiology of Prostate Cancer
While 1 in 6 males are diagnosed with CaP, approximately 2.5 million that have
been affected are among present CaP survivors in the USA (ACS, 2012). In 2012,
mortality from CaP is estimated at 28,170, with nearly 241,740 males among those newly
diagnosed (ACS, 2012). In fact, CaP accounts for the second highest cancer incidence
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rate among US males and was responsible for over 33,720 deaths in 2011 (ACS, 2011).
Although there is a decrease in incidence, there remain the need for improved therapies
and effective prevention strategies. This is especially significant since the disease appears
to affect at an average age of 67 (ACS, 2012).
While the disease has a higher incidence in males in Western countries, compared
to those in the Asian male population, pathological data indicates similar incidence of
latent disease, in approximately 80% of males ≥ 80 years old (Kumar & Anderson, 2002).
This lower incidence mentioned among males in the Asian population has been
associated with the potential protective activity of SDPs consumed in the diet of Asian
males (Kumar & Anderson, 2002). Figure 2 (page 11) provides context to the relationship
of incidence over time. Animal and in vitro studies have also shown that there is
significant anticancer activity from SDPs such as genistein and daidzein and that these
isoflavones may be responsible for the lower incidence of CaP and another condition
BPH observed among Asian males (CDC, 2010).
There is also concern that estrogens that were once effective in treating CaP,
might also be contributory to the development and progression of the disease (Bonkhoff
& Berges, 2009). Importantly, while this form of therapy appeared to be effective against
androgen-dependent disease, the potential risk of been associated with malignancy is
certainly disconcerting (Bosland, 2005). According to (Bosland, 2005) many theories
have explained this association including evidence of various genetic polymorphism in
particular codon regions of the ER-α gene that either increases the risk or development of
CaP. While ER-α has demonstrated this association of CaP development ER-β has
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demonstrated tumor suppression activity (Bosland, 2005; Giton, de la Taille, Allory, et
al., 2008). Age as indicated earlier is a significant predisposing factor for CaP. CaP
appears to be most likely initiated in gland cells and is referred to as adenocarcinomas
(ACS, 2012). These are the cells that are responsible for the production of the fluid that
improves the environmental conditions for sperm cells (ACS, 2012). Reports indicate that
CaPs can experience either slow or rapid growth, and evidence exists of the cancerous
tumors in older males but mortality been attributed to another disease condition (ACS,
2012).
The development of CaP can also be attributed to PIN lesions considered a
precancerous event and can affect males even in the early decades of life (ACS, 2012;
Weihua, Warner, & Gustafsson, 2002). Microscopic analysis of biopsied PIN cells and
determination of the level of their abnormality can be helpful in determining the chances
of developing CaP (ACS, 2012). There is also a greater chance of CaP occurring when a
high grade abnormality is assessed during PIN analysis (ACS, 2012). The presence of
high grade PIN on biopsy also reflects an increased possibility of (20% - 30%) greater
association with CaP development, and that there are cancerous lesions in other parts of
the body (ACS, 2012). Other important findings that may be indicated through the biopsy
process include atypical small acinar proliferation (ASAP) and proliferative
inflammatory atrophy (PIA) (ACS, 2012). While there is some uncertainty regarding PIA,
it is still thought of as a precursory event, while ASAP appears to indicate a need for
follow-up biopsy (ACS, 2012). This seem even more compelling when evidence indicate
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the presence of ER-β receptors in normal, hyperplasic and prostate tumor cells, but a
decreased expression in CaP (Weihua, Warner, & Gustafsson, 2002).
Prostatic Specific Antigen
PSA is a protein and falls in the group of serine protease, and is produced by
prostate tumors (Adams, Chen, Newton, Potter, & Lampe, 2011). Prostate tumors have
the ability to destroy protective barriers and allow PSA to spill into the blood. This allows
for serum PSA concentration to be employed as a useful tumor marker (Adams, Chen,
Newton, Potter, & Lampe, 2011). However, while the concentration of serum PSA
appears to be proportional to the tumor volume, it is also not always elevated during CaP
and other situations such as BPH, inflammation and other prostate conditions are
responsible (Adams, Chen, Newton, Potter, & Lampe, 2011). With increased use of PSA
as the screening method, there has been the detection of several asymptomatic cases
among tested populations, which could certainly account for a higher described western
incidence (Kumar & Anderson, 2002; Bonkhoff & Berges, 2009).
Consequently, the lack of available testing in some populations might also
account for undiagnosed cases which could increase the present number. Prevention
strategies might certainly be the model responsible for reducing the high incidence in
Western countries, and inclusion of dietary SDPs appears a potentially viable option. This
research aims to identify through meta-analysis of the data from selected randomized
controlled trials the dynamics that is evident through analysis and determination of the
ES of SDPs intervention. This thought is certainly shared by several investigators
(Landstrom et al., 1998; Mentor-Marcell, Lamartiniere, Eltoun, Greenberg, & Elgavish,
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2001; Morrissey et al., 2004), in reference to the influence of genistein to decrease tumor
cells in mice models. Inducing apoptosis in vitro by the SDP resveratrol in selected
prostate carcinoma cell lines also demonstrated evidence of SDPs on prostate
adenocarcinoma cell growth (Mentor-Marcell Lamartiniere, Eltoun, Greenberg, &
Elgavish, 2001). The true effect of SDPs will therefore be unearthed from this intensive
research process. The prostate gland located at the neck of the male urethra and bladder.
It is approximately the size of a walnut in younger adults but can be larger in older males
(ACS, 2012). Figure 4 below shows a healthy prostate with a walnut representation of its
normal size. Tumors and other infections of the prostate result in an enlarged prostate.
There is a variation in the size of the prostate and it is usually larger as the man ages.

Figure 4. Healthy Prostate, Nearby Organs and Internal Structures. Source: The Prostate,
National Cancer Institute, 2012.
In Figure 5 a representation of the prostate gland affected with a developed tumor
demonstrates the resulting enlargement. The enlarged prostate gland results in secondary
health issues as it causes constriction of the urethra. Constriction of the urethra is
associated with problem urinating and other medical issues.
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Figure 5. Prostate Gland with Identifiable Cancerous Tumor. Source: What is prostate
cancer? ACS, 2012.
In some contexts, it is considered both muscular and glandular with ducts that
open into the prostatic urethra and consist of a central and two adjacent lobes (NCI,
2012). The prostate gland enlarges with age and this can result in constriction of the
urethra and subsequent difficulty in the passage of urine (NCI, 2012). The processes that
encourage growth, differentiation, and functionality of the prostate gland while largely
dependent on the male hormone androgens, relies in some significant context to the
action presence of estrogens (Harkonen & Makela, 2004). The enzyme 5-alpha-reductase
acts on the male hormone testosterone an androgen produced in the testicles converting it
to dihydrotestosterone (DHT) which subsequently influences growth of the prostate
(ACS, 2012). The presence of male hormones during the adult life allows the prostate to
maintain its size (ACS, 2012), but several factors can influence changes that result in
unfavorable health conditions. Problems involving the prostate appear to begin during
later decades in life, although earlier problems can affect passage of urine through the
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urethra (NCI, 2012). Problems that can occur over time include infection (prostatitis),
benign prostatic hyperplasia (BPH) and CaP (ACS, 2012; NCI, 2010).
Screening Methods
CaP screening methods have afforded some amount of earlier opportunity for
active surveillance and early treatment. However, several concerns have arisen from the
use of the PSA test which is employed for many years as a major determinant for
initiating further screening, determining response to various therapies and to predict the
outcome from treatment. The PSA screening also takes into account the importance of
values as they relate to percent- free PSA, PSA velocity, PSA density and age-specific
PSA ranges (ACS, 2012). Complementary modalities including digital rectal examination
(DRE), prostate ultrasound (transrectal ultrasound), and prostate biopsy have been used
as independent screening tools (WebMD, 2010). However, these treatments have not
shown improved survivability and health outcomes (WebMD, 2012). Benefits of earlier
diagnosis and detection of latent disease achieved through development of improved
screening techniques (WebMD, 2010). Benefits we can appreciate, although
accompanied by uncertainties including a high incidence of false positive results (ACS,
2012). This can result in the unnecessary use of other procedures and high economic
costs (ACS, 2012).
PSA Testing and Importance
Approved by the US Food and Drug Administration (USFDA), the PSA test looks
at the level of serum PSA. The value ≥ 4ng/ml warrants further testing (NCI, 2012).
Other testing includes prostate biopsy for tissue analysis or monitoring of PSA velocity
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(NCI, 2012). These tests reflect changes in PSA levels over specified times (NCI, 2012).
Elevated PSA levels over time and a positive biopsy might be indicative of CaP (NCI,
2012). Cells are biopsied, and a Gleason score from 2-10 is assigned following analysis
(NCI, 2012). Some individuals have shown no increased health benefits from PSA
analysis (ACS, 2012). There is some controversy about the value of PSA analysis as a
valuable screening tool (ACS, 2012). Confirmation is evident with an observed mortality
rate of 3% within a population with a 9% diagnosed incidence rate (ACS, 2012).
Presently, there is about 2% - 2.5% mortality rate that occurs among the 18% diagnosed
following PSA screening (ACS, 2012). Mortality rate is within the context of reliability
regarding PSA values. Increasing PSA might not be significant of CaP, but from
prostatitis and BPH as indicated earlier. PSA is specific for its association with prostate
activity and is not itself specific for the association with CaP (Kumar & Anderson, 2002).
However, a rising PSA following surgical castration and following radiation is
certainly cause for concern and can be extremely problematic (Vaishamapayan et al.,
2007). Values that are provided through this screening method are therefore, indicative of
the possible risk of CaP with that risk increasing to ≥ 90% when the PSA level is >
20ng/ml if the considered level of 2.5ng/ml is considered normal for males between the
ages of 40 – 49 years old (Kumar & Anderson, 2002). Employing the digital rectal
examination (DRE) is another screening method that can detect abnormality of the
prostate gland (ACS, 2012). Tissue biopsy and microscopic analysis of cells is to confirm
the presence of cancer, and to determine the course of action regarding treatment or
surveillance (ACS, 2012). Screen due to factors such as age, ethnicity and genetics.
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Staging provides a good indication of how far the disease has spread following screening
assessment. The method most commonly employed by clinicians is the elaborate TNM
classification approved by the American Joint Committee on Cancer (AJCC) which
assesses the disease centered on the progression of the primary tumor (T), any evidence
of spread to nearby lymph nodes (N), and evidence of distant metastasis (M) (ACS,
2012).
Tumor Grading
An important part of diagnosing CaP is the staging process. Information on
staging comes from an understanding of the disease process. The disease process is
defined by a system that provides assessment based on the tumor containment or spread
to other tissues (ACS, 2012, NCI, 2012). Tumor spread and containment are important in
determining treatment options and other factors such as response to therapy and
subsequent outcome (ACS, 2012). Grading of tumors is an important part of the
therapeutic process. Grading helps to define the disease state and provides important
information on the present status of the disease (ACS, 2012). Both Gleason grade and
tumor node metastasis (TNM) staging are valuable screening methods, that are associated
with CaP diagnosis and are available to guide treatment modalities and the potential for
disease progression or containment (ACS, 2012). They are also extremely focused,
directed and elaborate scientifically based assessment of the disease process, and is
therefore invaluable in any therapeutic decision and follow-up care or employed curative
strategies. Below is the ACS (2012) outline of the application of the Gleason grade, Stage
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and Score in defining what approaches including chemotherapy, surgery, hormone
therapy and others might be best suitable for intervention and follow-up strategies.
Gleason Grading
Important to the understanding of tumors is what is considered the ‘Gleason
Grade’. The ‘Gleason’ grading system classifies tumors based on a staging scale of 1 – 5.
This staging scale is an indication of the disease at the time of diagnosis (ACS, 2012).
Grade 1 tumors have cells with the appearance of normal prostate cells (ACS, 2012).
Cells considered grade 5 on the tumor grading scale are abnormal and poorly
differentiated (ACS, 2012). These cells have now infiltrated the prostate and are
observable throughout that gland (ACS, 2012). Cells categorized between grades 2 – 4,
demonstrate varying increasing ranges of infiltration of tumor cells within prostate tissue
(ACS, 2012).
Important to understanding the state of the prostate tumor is through the Gleason
score. Gleason score is a complementary tool within the assessment process. Most CaP
tumors have mixed cell types with different tumor grades, and the Gleason score is an
additional assessment criteria (ACS, 2012). The Gleason score provides a better rational
analysis of the state of the tumor (ACS, 2012). Tumors are assigned two numbers which
helps to identify the designated dominant and minor tumors (ACS, 2012). Addition of the
numbers assigned to each tumor grade then provides a better assessment and subsequent
description of the present tumor through this assigned score (ACS, 2012). Therefore, a
dominant grade 2 tumor and a minor tumor grade 4 would classify as six on the Gleason
scoring scale (ACS, 2012). Appreciation of the value of the Gleason score comes with the
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understanding that scores range from 2 – 10 with a higher value representing tumors that
have a greater differentiation from normal prostate cells and those that are likely to be
aggressive in their ability to spread (ACS, 2012).
The preceding discussion, therefore represents a generalized outlook that a
Gleason score between 2 – 4 or Grade 1 cancer is the representation of cancer that can be
considered low grade and consists of cells that are highly differentiated (ACS, 2012;
NCI, 2012). A Gleason score between 5-7 or grade 2 cancer, represents a cancer that
consist of cells that are moderately differentiated (ACS, 2012; NCI, 2012). A score of 810 on the Gleason scale, represents a Grade 3 cancer, consist of poorly differentiated
cells. The grade 3 tumor represents tumors considered high grade (ACS, 2012; NCI,
2012). While poorly differentiated cells are possibly a definitive representation of high
grade tumor that needs aggressive treatment the problem concerned those cells which are
moderately differentiated as there appears to be no significant model of determining the
progression of these cells, and this is apparently a significant volume of the cancer grades
identified during diagnosis (ACS, 2012; NCI, 2012).
While grading provides invaluable information on proliferation of tumor cells
within the prostate tissue, another important tool within the broad diagnostic process, is
that considered staging. Here, is another tool which while complex in its assessment
provides even greater capability and context to the diagnosis process, in its ability to
providing a more thorough understanding of the disease in relation to the spreading of the
cancer outside of the defined gland (ACS, 2012). There are two recognized staging
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methods used during CaP staging. The one employed most during CaP staging which and
approved by the AJCC (ACS, 2012) is described. .
The American Joint Committee on Cancer System
A staging system is a standard way for the cancer care team to describe how far a
cancer has spread (ACS, 2012). The most widely used staging system for CaP is the
American Joint Committee on Cancer (AJCC) TNM system (ACS, 2012). The ACS
document indicates that there are five important areas regarding the TNM system (ACS,
2012). These are important determining factors for staging of the disease and certainly
could be important for influencing and employed treatment strategy. In this AJCC staging
system there are several important concerns. The concerns include the degree of the
primary tumor (T category), the presence or absence of tumor metastasizing and if lymph
nodes (N category) that are near the tumor are affected (ACS, 2012). These are the
components of the TNM system. The PSA level at diagnosis, the Gleason score following
surgery or when biopsied are also important in the diagnostic process (ACS, 2012).
Pathophysiology of CaP
While the development of CaP in humans is still defined by the difficulty in
establishing its true etiology, evidence suggests some similarity between the disease and
that described in male canine (Waters et al., 1998). According to this model, several
defining similarities exist between both species including the development of PINs, the
late onset of the disease, and the variation exhibited morphologically and genetically in
observed prostatic lesions (Waters et al., 1998). The canine model certainly appears to
explain several components of the disease. Among areas that are defined through this
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similarity and support the use of the canine model are progression of the disease, ability
to define predisposing factors and testing of therapeutic agents (Waters et al., 1998). The
issue of PIN progression to tumor growth and subsequently metastasis of the disease is
therefore important (Waters et al., 1998).
However, while the above is indicative of the positive value of other mammals in
understanding CaP tumor, (Maini et al., 1997) there is an indication of limitations
including reduced spontaneity, and the fact that canines are more difficult to manipulate
genetically. Employment in this type of research could also be potentially expensive.
With problem depending on mammalian models to understand CaP development, using
transgenic mice have been valuable. The transgenic mice allows for understanding the
importance of neuroendocrine cells in CaP development. Neuroendocrine cells are rare
within the prostate. However, they contribute significantly to the development of very
aggressive prostate adenocarcinoma that is also observed in humans (di Sant’ Agnese,
1998). The transgenic mice model is also of tremendous value in attempting to
understand the issue of CaP development without androgen stimulation. , although
preceded by the presence of PIN and a rapidly metastasizing tumor (Garabedian et al.,
1998).
CaP is still a very difficult disease to understand and transgenic mice model
provides a valuable opportunity to study the neuroendocrine disease development and the
complex role of neuroendocrine cell type in disease etiology (Garabedian et al., 1998).
Transgenic mouse models’ do provide some insight into possible development of CaP,
but the value xenographs, representative of human CaP lines such as LNCaP and CWR-
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22 have in some context seen some difficulty because of species differences (Stearns et
al., 1988). However, their use has provided important context to the issue of
chemoprevention and drug development (Stearns et al., 1998). What appears to be of
interest regarding the use of mammalian models to understand CaP development and
progression is the combination of many interacting factors and ones that illustrate a
complex disease. These complex associations are also likely to be integral in not only
development of the disease but the progression, metastasis and the complex nature of
recurrence.
Biology of the Prostate
The prostate gland is about walnut size and located at the neck of the male’s
urethra and bladder. The gland is both muscular and glandular and has ducts that opens
into the prostatic urethra; it has a central, right, and left side adjacent lobe (ACS, 2012).
While several important functions are attributable to the prostate gland, with age there are
important changes that can lead to conditions including benign prostatic hyperplasia
(BPH) and CaP (ACS, 2012). With age increase, the prostate undergoes growth changes
including a doubling in size during puberty (ACS, 2012). However, while the prostate
continues to grow throughout the lifespan of men, enlargement can occur and result in
problems, especially after the age of 60 (ACS, 2012). In fact, greater than 50% of BPH
cases occur after that age and increasing age poses a greater risk (ACS, 2012). BPH is
associated with thickened bladder wall, irritation, frequent urination, and urgency even
when there is only a small amount of urine. Although BPH is a natural part of the aging
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process, a decrease in the ratio of testosterone to estrogen hormonal levels can result in
increased prostate growth (ACS, 2012). Estrogen is predominantly a female hormone.
A second theory implicates the continued production of dihydrotestosterone
(DHT) a substance derived from testosterone and which controls prostate cell growth
(ACS, 2012). The continued production of DHT and its storage in the prostate, even with
the reduced production of an age decreasing testosterone, results in continued cellular
growth (ACS, 2012). A third theory emphasizes the concept of cellular instructions from
earlier initiated instructions for cellular growth. Cells that have early growth initiated
instructions, could themselves resume growth or provide growth instructions to other
cells. Instructions could involve greater sensitivity to hormones that could then influence
growth (NKUDIC, 2010). This theoretical model could explain since cellular activity is
continually under biological influence. The DPIM also addresses chemoprevention under
these conditions and therefore provides the best model for this study.
Staging
Staging is an important part of diagnosis and the therapeutic process. There is also
a greater understanding of the disease and certainly an opportunity for discourse between
health care professional and individual. There are two staging methods associated with
CaP diagnosis (ACS, 2012). The clinical stage provides an opportunity for the physician
to have the best estimation of the present disease status (ACS, 2012). Several areas
including findings from laboratory tests, prostate biopsy, and physical examination
including the DRE, and imaging studies are very valuable (ACS, 2012). The second stage
or pathologic stage, when analysis of extracted tissue is completed (ACS, 2012). Staging
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types can result in differences in assessing cancers for staging since tissue removal and
assessment could indicate a change in location of cancer cells (ACS, 2012). Staging also
provides a realistic assessment of the cancer, as it provides a more detailed assessment of
the disease process (ACS, 2012). Pathologic staging is dependent on analysis of the
removed tissue, then it might be appreciated as advantageous in employing radical
prostatectomy than the modalities of watchful waiting (expectant management) or
radiation therapy’ (ACS, 2012).
Staging employs various categorical assessments in determination of CaP disease.
However, the category denoted as T1 is not among those used when defining pathologic
staging of the disease (ACS, 2012). The staging categories presented provides a brief
description of this process (ACS, 2012). There are four (4) categories for clinically
describing the local extent of a prostate tumor, ranging from T1 to T4 with most
consisting of subcategories (ACS, 2012). The N categories describe whether the cancer
has spread to nearby (regional) lymph nodes (ACS, 2012).The M categories describe
whether the cancer has spread to distant parts of the body with the most common sites of
CaP spread been bones and distant lymph nodes (ACS, 2012). The lungs and liver are
other tissues, which CaP can affect (ACS, 2012).
Estradiol
The secretion of E2 is from ovaries in females. E2 is an estrogen hormone.
However, males secrete smaller quantities between 5-40 pg/ml. Studies have also shown
the effectiveness of E2 for cancer chemoprevention.
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Stage Grouping
Stage grouping follows a determination of the T, N, and M categories (ACS,
2012). Stage grouping is the cumulative assessment of CaP staging, Gleason scoring and
prostate-specific antigen (PSA) concentration (ACS, 2012). If Gleason, score or PSA
concentration is absent then staging relies on the T, N, and M categories (ACS, 2012;
NCI, 2012). The use of Roman numerals provides an indication of how advanced the
when diagnosed. Cancers that are least advanced is represented by the numeral I and IV
and provides a representation of the most advanced cancer (ACS, 2012). This
representation through numeric values help to determine what options are available for
treatment and the prognosis for survival outlook (ACS, 2012). A second staging model
the Whitmore–Jewett system has staging algorithm based on A, B, C and D staging. Less
use is made of the Jewett system in the clinical setting (ACS, 2012). However, if used
during the screening process, effort should be to provide comparative assessment based
on the more widely employed TNM system (ACS, 2012).
Dual Prevention Integrated Model
The study initially considered the putative multistep cellular biochemical pathway
model by Giovanni (1999). While this theoretical concept defines a biochemical pathway
to CaP etiology and provides some constructs for the theoretical basis of this study, it
does not address the primary and secondary basis for chemoprevention within the public
health framework. The DPIM (Michelin & Gutierrez, 2013) presented in Chapter 1 is an
original framework addressing the conceptualized primary and secondary strategies
needed to address the process of CaP and other cancers. The DPIM is structured on the
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premise that dietary intake levels of SDPs, in particular genistein and daidzein, are
associated with the prevention of cellular damage responsible for the lower incidence of
CaP observed among males in Asian countries. Theoretical models proposed in the
literature have identified mitigating factors that result in cellular biological activities
leading to development and progression of CaP. The goal of these models and of this
research is the elucidation of factors which if manipulated could reverse or prevent CaP
disease by addition of specialized isoflavones within dietary or medicinal contexts able to
avert progressive development of prostate tumors. Among the mitigating factors, age,
inflammation, change in hormonal status and genetic mutations are key. While several
studies have provided scientific support for the events describing such association at the
cellular level, a primary prevention approach has not been taken into consideration.
Therefore, in addition to the conceptual approach, meta-analysis of the relevant literature
and determination of the true ES of SDP intervention on individuals with various stage,
grade or type of CaP remains an important gap in the literature.
The model defined by Michelin and Gutierrez (2013) guides the conceptualization
of this study providing a framework for initiating dietary SDPs as a chemoprevention
strategy. The early evidence of damage to the normal prostate tissue resulting in genetic
mutation and cellular damage (Giovannucci, 1999) provides an early opportunity for this
chemopreventive access. In contrast to the development of neoplasia as decribed in the
model by Giovanucci (1999), the DPIM focuses on preemptive chemoprevention through
SDPs to prevent and reduce early prostate tissue damage (Michelin & Gutierrez, 2013).
Averting further tissue damage by implementing DPIM strategies is the primary

57
prevention function. Other therapies including Androgen Deprivation Therapy (ADT)
and other chemotherapeutic agents might provide some positive response (Giovannucci,
1999). SDPs can also function where ADT is required and have shown to be successful.
The proposed study also addresses the problem of recurrence and identification of
potential failure for any successful therapeutic intervention. Through the DPIM the study
demonstrates the opportunity for SDP chemoprevention. There is also the potential for
immunotherapeutic exploration. The model certainly accounts for that prospect through
the indication of antibody intervention. Other models include the role of oxidative stress
(Thapa & Ghosh, 2006) and environmental factors in the disease process. The context of
the seminal role of the proposed study allows for greater application of the Michelin and
Gutierrez (2013) model at it sought to determine the ES of SDP intervention and the
potential for chemopreventive treatment.
Additional research has also demonstrated the value of antioxidant enzymes (Jung
et al., 1996) during in vitro antitumor analysis. Genistein is also a valuable inhibitor of
CaP cell proliferation through activity that affects the EGFR-Akt/p70S6K pathway and
by down regulating important androgen receptors (Oh, et al., 2010). Genistein’s use
supports the hypothesis that values plant derived compounds as effective biological
antitumor agents. This evidence is provided through several in vitro studies that have
implied an inverse activity in endocrine-resistant tumor cells (Lian et al., 2003), such as
apoptosis through the activity of a flavonoid derivative (Chan et al., 2000; Patra et al.,
2011), and down regulation of PSA (Han et al., 2007). Hormone refractive CaP following
radical prostatectomy (surgical castration) poses tremendous challenges even with the
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best medical therapies and is associated with poor survival outcomes (Hess-Wilson &
Knudsen, 2006). Meta-analysis of selected randomized controlled trials involving CaP
patients between 50 and 70 years old allowed better understand of the defining principles
that allow SDPs such as genistein and daidzein to valuable for chemoprevention. Even
within the context, that CaP could also be hormone driven through the intricate
associations of estrogens and testosterone (Maskarinec et al., 2006).
Difficulty in treating hormone refractory CaP (Celhay et al., 2010) has resulted in
the employment of combinations of presently used drugs such as paclitaxel (taxol) (Ping,
Hour, Ling, & Yu, 2008). Other combinations include employing several plant based
compounds including antioxidants, epigallocatechin gallate and genistein (Ping, Hour,
Ling, & Yu, 2008). Studies employing TRAMP mice at different stages of the
developmental process throughout life showed the latter establishing an approximate 50%
reduction in the development of poorly differentiated prostate tumors when compared to
controls (Wang, Eltoum, & Lamartiniere, 2007). These studies are supportive of evidence
from epidemiological data implicating the presence of soy in Asian diets as the rationale
for this lower CaP incidence.
Estrogens and Cancer Etiology
There is valuable information that provides support to the role of estrogen in
cancer etiology (Ganry, 2005). The inverse relationship between estrogens and cancers is
continually reported (Kumar et al., 2011). However, greater role for SDPs is necessary
due to the increase in adverse event become associated with exposure to animal derived
estrogens (Colli & Colli, 2005). Plant derived SDPs include genistein and daidzein two
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major phytochemicals, which are the focus of this study. They have become associated
with chemoprotection and the beneficial association in decreasing CaP incidence seen in
some populations (Dalais et al., 2004). The ES of such biochemical activity is the focus
of this intensive discourse. It will provide a better evaluation of the true relationship
between the effect of SDPs and response in PSA and E2 levels. These are valuable
markers for cancer progression or therapeutic response. Estrogen is important to many
biological events including the early initiation of prostate development; however, as
indicated there is also some supportive evidence of its role in CaP development (Ganry,
2005).
However, this premise is open to some amount of criticism since there is also
evidence of CaP recurrence following surgical castration, and therapy employed to
disrupt hormonal activity in the prostate gland (Feldman & Feldman, 2001; Hess-Wilson
& Knudsen, 2006; Leewansangtong & Soontrapa, 1999). What is apparent is that the
models by (Giovannucci, 1999) and (Thapa & Ghosh, 2004), appear to be significantly
opposite in the approach to describing CaP development. The model by (Thapa & Ghosh,
2004) links the metabolism of androgen to the development of CaP (Friedman, 2005).
Certainly, there is a close association between hormonal influence and early initiation of
prostate development. Subsequently, the continuing influence of hormones can be a
determining factor in the early development of the disease. Ross et al., (1998) implies, the
evidence expounded regarding such link, might lack any realistic context. This argument
certainly demonstrates a need for further understanding CaP development. Defining how
such biological activity through isoflavones such as genistein can influence disease
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prevention or developmental delay is also prudent. A second model associates androgen
administration to the development of the disease (Prehn, 1999). Suggestions regarding
androgens as an important initiator for CaP development come from earlier evidence
regarding a developmental association between the prostate gland and that hormone
(Ross et al., 1998). However, questions were again raised regarding the issue of hormone
independent CaP, which has allowed for hypothesizing a broader developmental
construct for the disease (Ross et al., 1998). Subsequently, a more recent genetically
associated model the Estradiol-Dihydrotestosterone (E-D) is now been suggested (Ross et
al., 1998). The E-D model is defined through a complex of interactions of specific genes,
and provides value to ethnic factors that has been proposed (Ross et al., 1998). This study
examines the context of ES based on these factors, since hormonal response is associated
with the basis of SDP activity. Here, the levels of PSA and E2 are among the markers
that allow for examination of such posited association.
Analysis of SDP intervention data provides some context to the value of soybased diets and the role of particular isoflavones such as genistein and daidzein in disease
prevention/treatment will be central to this research process. The estrogenic activity of
SDPs and the influence hormones such as E2 during the therapy was determined from the
analysis process. Research has indicated that soy derived SDPs such as those referenced
throughout this discourse and especially genistein possess strong antioxidant properties
important in the chemoprotective ability. The need to understand the true effect of SDPs
on CaP is also within the context of the presentation of some results from studies
categorized as inconclusive following data analysis (Nakamura et al., 2011). In a study
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employing mice, there is reference made to the progression of tumors to secondary
organs and associated with lymph node infiltration (Nakamura, et al., 2011; Napora, et
al., 2010). However, (Swami, et al., 2005) present results which are the contrary to those
previously reported and mention the inhibitory effect of the isoflavone genistein during in
vitro analysis on DU 145 human CaP cells.
Estradiol and PSA
Numerous studies allude to the changes that occur over time in relation to the
influence of both the disease state and the intended intervention on PSA and E2 levels in
the prostate gland. The reference range for E2 among adult males is 10-40 pg/ml (Adams,
Chen, Newton, Potter, & Lampe, 2004); Kumar et al. 2007); Miyanaga et al., 2012;
Schroeder et al., 2005; & White et al., 2010). There appears to be a certain amount of E2
hormone produced in males. Evidence points to a decrease in E2 during the CaP disease
process. Presence of SDPs appears to have a positive relationship with E2 levels in the
prostate gland. Therefore, intake of SDPs will have a direct increase in estriadol and
decrease disease progression. However, the inverse relationship occurs between SDPs
and levels of PSA. PSA is the marker employed to assess either tumor presence, response
to therapy, and in some context the evidence of any health outcome. The literature is also
marked with uncertainties, a dilemma that still confronts those diagnosed or treated for
CaP. Numerous in vitro studies have demonstrated a positive chemoprotective role from
SDPs on different tumor cell lines (White et al., 2004), but conflicting evidence is
presented when human trials have been conducted (Sharma et al., 2009). Some studies
reflect positive associations, but the strength of those associations has not undergone
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rigorous examination. The magnitude and direction of the association was determined
through this dissertation.
Evidence and Interpretation of CaP Development and Treatment
Both evidence and interpretation proposed for the initiation, progression and
failure of ADT and other therapies differ. While most theoretical models support the role
of several factors including age, genetic mutation, exposure to environmental toxicants
and nutrition, as important, the central dogma reflected through those theories seems to
focus on the influence of Reactive Oxygen Species (ROS). Different explanations
regarding tumor initiation and the subsequent events that are responsible for hormonal
and PSA fluctuations have been provided as well. Diet as implied, is among the factors
that have an influence on the development and progression of CaP. Such concern is
shared by (Marks et al., 2004) when looking at the differences in prostate tissues in males
living in both westernized and an Asian locale, but from a similar ethnic background.
While the conclusion from this study supports the importance of environmental factors in
predisposing to CaP development, those factors such as lower E2 and urinary soy
metabolites levels provided important correlational context. In this study, both were in
Japanese American males than Non Japanese males, which could be indicative of lower
consumption of soy-based products. Loss or absence of phytoprotection attributable to
SDPs could certainly be an integral factor in allowing disease progression.
In the theoretical model proposed by Khandrika, Kumar, Khoul, Maroni & Koul,
(2009) the damaging implications of ROS on cellular structures such as nrf2 and
disruption of specialized nrf2-nRE axis appear more pronounced during a lower
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antioxidant environment. Progression and the subsequent detriments of cellular damage
from increased ROS also appear to target cells that have a greater antioxidant capacity
therefore, exposed to greater damage (Khandrika, Kumar, Khoul, Maroni & Koul, 2009).
Similar opportunity for antioxidant damages were observed in an earlier model (Valko,
Rhodes, Monkol, Izakovic, & Mazur, 2006). Here, there is cellular damage resulting from
ROS, which leads to DNA damages. This subsequently progresses to preneoplastic
conditions and could potentially progress irreversibly, leading to a cancerous state
(Valko, Rhodes, Monkol, Izakovic, & Mazur, 2006). This model certainly accounts for
similar factors such as oxidants and carcinogens that places stress on the homeostatic
condition, and subsequently leads to the precancerous state with further potential for the
development of cancerous lesions (Khandrika, Kumar, Khoul, Maroni & Koul, 2009). It
appears that with the initiation of antioxidant intervention, through SDP inclusion, that
cellular damage could be delayed, prevented or reversed (Khandrika, Kumar, Khoul,
Maroni & Koul, 2009). Support for this is presented in the research by Borek (2005)
when there is mention of antioxidants as potentially useful for preventing certain cancers
that are known to be hormonally regulated. The evidence supports that among these are
CaP, breast and endometrial cancer. The results from this study could be important in
defining how other cancers are approached within the context of prevention, treatment
and management of the disease.
This is important especially since breast cancer among females have a 10-20%
recurrence following initial treatment, which is associated with a five-year cancer-free
status (Borek, 2005). Also important is the recurrence associated with CaP which was
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mentioned earlier in this discussion and is considered to be between 18 – 24 months
(Reference). While antioxidants such as vitamin E and C are employed to prevent
recurrence in many females, a similar trend in use has also been seen in males diagnosed
with CaP. Antioxidant activity, which has become associated with SDPs might certainly
play an important role in the lower CaP incidence. While these models appear to
introduce the variable of SDP within the disease process, post-cellular destruction by
factors responsible for initiating CaP development is still evident.
Another important view on possible prevention of CaP development, is posited
through the mediation of topoisomerase II activity which is an important enzyme in DNA
synthesis (Patra et al., 2011). Here, topoisomerase II∞ is seen as the predominant enzyme
in cells that are proliferating and is therefore significantly expressed in tumor cells (Patra
et al., 2011; Hsinang et al., 1988; Heck & Barnshaw, 1986).
Literature on Methodology of Studies on SDP and CaP
Meta-analysis was the methodology employed for this study as it allowed for
greater understanding of the ES response of SDP treatment on the populations assessed
through different studies selected for this research. An appreciation of this study certainly
provides the opportunity to conduct what can also be considered ‘quantitative syntheses’,
of the data obtained from primary research employing statistical methodology (DeCoster,
2004). In reference to thoughts shared by (Marsh, Johnson & Carey, 2001), employing
meta-analysis will also provide a more in depth understanding and explanation of those
integral associations between SDPs and the initiating biochemical, environmental and
personal factors that result in disease development and progression. This in depth
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appreciation of the value of meta-analysis allows for employing it as a tool for statistical
evaluation of interventions and the subsequent success that can be attributed to their
implementation (Marsh, Johnson & Carey, 2001).
The larger population size made possibly by pooling several studies and analyzed
through meta-analysis provides the probability for even greater reliability and validity of
the findings. The analysis therefore provides more value to the intervention process and
improves its reliability and validity. In medicine meta-analysis seeks to assess
intervention in terms of ‘treatment effect’, and this can sometimes be referenced through
statistical measures such as odds ratio (OR), risk ratio (RR), or risk difference (RD)
(CMA, 2006). In relation to studies focused on the social sciences, meta-analysis
employs the term ‘effect size’ in reference to ‘standardized mean differences and
correlations’ (CMA, 2006). However, both references can be employed during metaanalysis application and is reflected throughout this study. However, while the use of
some statistical tools including Cohen’s d, multiple regression and ANOVA can be used
to generate “treatment effect or [ES]” data. The availability of a professionally designed
comprehensive meta-analysis software, allows for even greater specificity, validity and
improved reliability of the computed data. Such professionally designed analytical
software allows access to all statistical tools in an individual package and employed to
generate more statistical reproducible results. While two forms of meta-analyses are
available, this study will employ the method designed to analyze quantitative research
literature. This study as implied will be a meta-analysis of the effect of soy derived SDP
compounds on PSA and E2 levels before and during intervention. How such an
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intervention can be quantified as a consequence of the “Effect size or Treatment size”
observations will be studied (CMA, 2006). This reference is pertinent since there are both
treatment and control groups involved in these studies and the resulting evidence is
generated from a contrast between sometimes quite differing interventions (CMA, 2006).
While some studies that seek to understand an effect but has no evidence of treatment
intervention, this would be defined as a more thorough “effect size” association (CMA,
2006). This study also exemplifies the dual role of different statistical measures (CMA,
2006). Using these tools as part of the methodology process, will allow for closer scrutiny
of data output, and the opportunity to understand various context of that data as it relates
to the size of the effect when multiple regression and Cohen’s d are employed for
analysis.
Summary and Transition
This chapter has provided information regarding different aspect of the present
state of the research regarding CaP and particularly to that relating to the issue of SDPs,
as prudent chemopreventive or therapeutic agents. Other models suggest, there are many
factors that contribute to the development and progression of CaP. Significantly, while
there is some indication of intervention following cellular damage and possibly where
this might be irreversible, none of the models appear to present earlier isoflavone
intervention, or an ES response to therapy employing these plant derived compounds.
There is similarly a lack of definitive evidence in the context of SDP intervention,
through research, that also provides a defining relationship between the effect of SDPs
and PSA and E2 levels. Therefore, while the literature points to a decrease in PSA and E2
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in pre-cancerous situations, there still needs to be statistically defining correlational
assessment since those values might not singularly reflect disease state. Positive
treatment response or therapeutic outcomes might also be absent. Meta-analysis was done
using selected randomized-controlled trials will be able to provide greater appreciation
for the value of SDPs in managing many aspects of CaP development. The next chapter
will therefore provide a through outline of the process to be employed in conducting this
research. It will outline the value of meta-analysis within public health research and
especially in understanding issues relating to disease intervention strategies and response
to those interventions.
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Chapter 3: Research Method
Introduction
The purpose of this study was to determine the ES, magnitude, and direction of
PSA and E2 serum levels following chemoprevention using the SDPs genistein and
daidzein. The response of serum levels of PSA and E2 are important markers for
therapeutic response and prognosis for different types of CaP disease outcome. Analysis
focusing on this cohort of US men is deficient. The REM answered five major theoretical
questions relating to the intake of dietary SDPs and subsequently the response of serum
SDP, PSA, and E2 levels. Odds ratio (OR) employing the 2x2 contingency table was
used to determine the effect of SDP the independent variable on dependent variables
serum SDP, PSA and E2 levels. Meta-analysis was used to determine the cumulative ES
and magnitude and direction of the independent variable on the various dependent
variables. This chapter describes the research design and approach to determine the
influence of chemoprevention using dietary SDPs. The effect of the intervention in
influencing change in serum levels of PSA and E2 was determined. The published
articles used in this meta-analysis comprised of the instrumentation and materials. The
data collection process described the initial search strategy and how the literature was
sorted prior to selection of those that met the study criteria. Finally, the data analyses
section reviewed the research questions and hypotheses and the use of the REM to assess
the ES.

69
Research Design and Approach
Meta-analysis is the approach and design employed in conducting this study. The
approach follows that used by many researchers including Ma, Qin, Wang, and Katoh
(2008). It is important to appreciate this as a method which provides an opportunity to
conduct what can also be considered quantitative syntheses of the data obtained from
primary research through the employment of a statistical methodology (DeCoster, 2004).
In reference to thoughts shared by Marsh, Johnson, and Carey (2001), employing metaanalysis also provided a more in depth understanding and explanation of those integral
associations between SDPs and the initiating biochemical, environmental, and personal
factors that result in disease development and progression. The in-depth appreciation for
the value of meta-analysis allowed it to be employed for reliable statistical evaluation.
These evaluations include examination of interventions and determining if any reported
success or failure is attributable to the inclusion or lack of implementation (Marsh,
Johnson, & Carey, 2001).
Meta-analysis is beneficial to the research process and demonstrates the ability to
sythesize systematically the ES findings among several studies (Kraemer, 1983). This
provided a broader platform on which to evaluate the effects of a particular intervention
(Kraemer, 1983). The value of meta-analysis to combine several studies therefore
allowed for the cumulative determination of correlation or association between variables.
This occurred in this study as treatment and responses were analyzed on the effect seen
within broader population. Variables were coded and the true effect size of the
intervention was determined through the indicated analytical applications. Those included
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OR, Hedges’s g, and the RMD that demonstrated the association between test variables
and response outcomes. Meta-analysis allowed for analysis of a larger population. This
analysis provided increased probability of greater reliability and validity to be expressed
by the meta-analysis findings. In medicine meta-analysis seeks to assess intervention in
terms of treatment effect. Treatment effect can be acknowledged through statistical
measures such as odds ratio (OR), risk ratio (RR), or risk difference (RD; CMA, 2006).
In relation to studies focused on the social sciences, the term effect size, is
applicable in meta-analysis (CMA, 2006). Another term that is applicable is the
standardized mean differences and correlations (CMA, 2006). However, both references
could be employed during meta-analysis application and is reflected throughout this
study. In addition, while the use of some statistical tools including Cohen’s d, Hedges’ g,
Odds ratio (OR), multiple regression and ANOVA can be used to generate treatment
effect size data, through the availability of the professionally designed CMA software,
allowing for greater specificity of the computed data. Inclusion of all separately indicated
ES tools provided ready availability and access to all reliable statistical tools.
While two forms of meta-analyses are available, this study employed that defined
to analyze quantitative literature research. This study as implied studied the effect of
SDPs on PSA and E2 levels before and after intervention and assessed its effect relative
to the effect size or treatment size observed (CMA, 2006). This reference is pertinent
since there are both treatment and control groups involved in this study and the resulting
evidence is generated from a contrast between intervention and control/placebo (CMA,
2006). In studies that sought to understand an effect but with no evidence of treatment
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intervention, defining those would be done through an “effect size” association. This
study exemplified the dual role of both statistical measures (CMA, 2006). Using these
tools as part of the methodology process allowed for closer scrutiny of data output and
the opportunity to understand various context of that data as it relates to the size of the
effect when multiple regression and Cohen’s d are utilized within the analysis process.
Setting and Sample
The sample for this study was obtained from eight RCT studies, yielding 527
participants. One advantage of meta-analysis is to provide a larger population on which to
determine the effect of the intervention, a valuable tool for ES measurement (Wilson,
2010). Determination of the magnitude and direction of the intervention is an important
facet of any study (Wilson, 2010). SDPs were the independent variables, and manipulated
relative to population size, age of participants and the duration of the study. Metaanalysis use of REM, and Hedges’ g statistic are among those that can mitigate against
any error or confounding in and between studies. Similarly, the dependent variables,
which included PSA and E2 serum concentration, considered population size as an
important factor. Other variables including age, duration and volume of SDPs and other
study factors that could influence results were controlled through meta-analysis.
Instrumentation and Materials
The analytical method followed in designing this study to investigate the doseresponse effect of SDP intervention on PSA and E2 levels is illustrated in Figure 1
(Chapter 1, page 4). The characterization of the studies followed the pattern outlined
below. Measures available included study name, study author, length of the treatment
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(days), number of subjects involved, the type of intervention, cancer status of the
subjects, age of the subjects, indices employed in generating scores for the DV that were
assessed (i.e PSA value before and following treatment with either Genistein, Daidzein or
both Genistein and Daidzein), the score associated with the calculated response (+/-), and
the outcome experienced following the employed intervention. The weighted mean
difference of PSA and E2 levels was determined at 95% CI for the treatment initiated in
each RCT and presented in a tabular format. A forest plot of the differences in PSA and
E2 values resulting from SDP intervention produced the overall mean and OR of the
effect of the intervention.
Variables
The independent variable in this study consisted of the various quantities of the
SDPs genistein and daidzein. The dependent variables in this study included dietary and
serum E2 and PSA levels following treatment employing genistein and daidzein.
Several tools used in the statistical analyses included the prior indicated ‘effect
size’ statistics such as OR, CMD, correlation, and Hedges’ g. These are all available in
the CMA (statistical software) (MetaStat, 2012). They ensure the study’s reliability and
validity of the resulting data (Campbell, French, & Gendreau, 2009). These instruments
and materials were associated with data collection and were integral to the meta-analysis
employed in this study to determine the ES. These determined the association between
the studied intervention and the experimental groups regarding SDP intake and PSA and
E2 dose-response.
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Data Collection and Statistical Analyses
The data were retrieved from eight published randomized-controlled trials
(RCTs). These studies had employed both treated and control designed experiments.
There are two methods of conducting meta-analysis namely (a) fixed and (b) random
effects models (Borenstein, Hedges, & Rothstein, 2007). In this research, the REM will
be employed as it appears more suitable for determining relationships sought including
the important process of ES (Borenstein, Hedges, & Rothstein, 2007). As different RCTs
have been employed factors such as age and intake duration not accounted for in the
studies, could result in different ES results (Borenstein, Hedges, & Rothstein, 2007). The
REM also allows for diminishing the random error that can be present within individual
studies, through the expansion of the sample size resulting from the use of different
studies (Borenstein, Hedges, & Rothstein, 2007). In fact, employing the REM in this
research could seem more prudent since the fixed effect model (FEM) assumes a similar
ES from all the studies which in fact might certainly not be affirmed and would be
remedied through use of the REM (Borenstein, Hedges, & Rothstein, 2007). The
principle therefore in employing the REM was based on the premise that the mean of the
different effects is a better representation of the true effect of the intended intervention
(Borenstein, Hedges, & Rothstein, 2007).
The meta-analysis process consisted of screening several hundred articles looking
at the effect of SDPs using randomized controlled trials. Studies that employed in vitro
and other study methods provided reference information. Presented below (Figure 6) is
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an outline of the research process. The research process included the complete process of
selecting and eliminating appropriate RCTs.

Search criteria defined, screening and identification of
potential articles that might be relevant for this study
Exclusion of non-RCT articles and those not
meeting other study criteria
Selected RCT articles were subjected to further evaluation

Further selection and exclusion occur to meet
defining inclusion criteria

The articles for this meta-analysis were selected from the
available applicable studies
The basis for withdrawing any identified RCTs
prior to the final selection are provided.

Selection of RCTs that met study’s criteria carried out from
the available group of studies.
Figure 6. Selection Process of RCTs included in Meta-Analysis. Source: Michelin, 2012.
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Research Questions and Hypotheses
The ingestion, duration and concentration of SDPs are responsible for the
associated lower incidence of CaP, and other prostate diseases observed among Asian
males. Inversely, its decreased intake among males in Western countries appears to be
associated with a higher incidence of CaP and other prostate diseases. A number of
questions therefore, need to be answered that may provide some perspective on the
effects of different independent variables on dependent variables and subsequently on
disease outcome among males in Wetsern countries. The proposed study seeks to answer
the following questions:
Research Question 1: Is there a correlation between dietary SDPs and serum SDP levels?
Null Hypothesis H1o: There is no correlation between dietary SDP levels and
serum SDP levels.
Alternative Hypothesis H1A: There is a correlation between dietary SDP levels
and serum SDP levels.
Statistical Plan: IV=Dietary SDPs; DV=Serum SDP; Statistical Test=θi = μi + ζi
Research Question 2: Is there a correlation between dietary SDP levels and serum PSA
levels?
Null Hypothesis H2o: There is no correlation between dietary SDP levels and
serum PSA levels.
Alternative Hypothesis H2A: There is a correlation between dietary SDP levels
and serum PSA levels.
Statistical Plan: IV=Dietary SDPs; DV=Serum PSA; Statistical Test=θi = μi + ζi
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Research Question 3: Is there a correlation between dietary SDP levels and serum E2
levels?
Null Hypothesis H3o: There is no correlation between dietary SDP levels and
serum E2 levels.
Alternative Hypothesis H3A: There is a correlation between dietary SDP levels
and serum E2 levels.
Statistical Plan: IV=Dietary SDPs; DV=Serum E2;
Statistical Test=Ti = θi + εi
Research Question 4: Is there a correlation between serum SDP levels and serum PSA
levels?
Null Hypothesis H40: There is no correlation between serum SDP levels and
serum PSA levels.
Alternative Hypothesis H4A: There is a correlation between serum SDP levels and
serum PSA levels.
Statistical Test: IV=Serum SDPs; DV=Serum PSA;
Statistical Test= Ti = θi + εi
Research Question 5: Is there a correlation between serum SDP levels and serum E2
levels?
Null Hypothesis H5A: There is no correlation between serum SDP levels and
serum E2 levels.
Alternative Hypothesis: There is a correlation between serum SDP levels and
serum E2 levels.

77
Statistical Test: IV = Serum SDPs; DV=Serum E2;
Statistical Test = Ti = θi + εi
Random Effects Model
The graphical outline below (Figure 7) is an indication of how various factors
influence the mean effect in the REM. This provides an ability to generate even more
reliable data.

Figure 7. Random Effects Model. The observed effect T1 (▄) is sampled from a
distribution with true effect θ1 (●), and variance σ2. This true effect θ1, in turn, is sampled
from a distribution with mean μ (♦)and variance τ2. Source: Borenstein, M., Hedges, L.,
Higgins, J., & Rothstein, H. (2009). Meta analysis, Fixed-Effects vs Random-Effects.
Introduction to Meta-analysis. John Wiley & Sons, Ltd. “with permission”
The following formula provides some context regarding the calculations as they
effect, μ = mean of all true effects, ε1= within-study error, ζ1 = between-study error
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(Borenstein, Hedges, & Rothstein, 2007). An observed effect, the following formula is
applicable and will be useful in arriving at this statistical measure:
Ti = θi + εi = μi + ζi + εi (Borenstein, Hedges, & Rothstein, 2007)
Subsequently, employing and calculating the Q statistics will provide evidence of the
total variance between studies. Q is represented through the following equation
(Bowden, Tierney, Copas, & Burdett, 2011).
These formulas will be important in ensuring detail statistical analysis. These
formulas also help to eliminate any errors ‘in studies and between studies’ (Borenstein,
Hedges, & Rothstein, 2007). Formulas reduce the potential for confounding which could
influence the degree of reliability and validity within the output data. These conditions
will be evaluated in subjects diagnosed with and had been treated for CaP at various
stages of the disease. The REM is therefore the most suitable method that will be
employed in this study, which will allow understanding the true effect of the separate
interventions, subsequently combined and as they would be defined throughout a more
expansive population.
Consumption of soy based products at different levels and concentrations have
been used to determine any relationship between and chemoprotective capacity relating
to both newly diagnosed and hormone resistant CaP individuals. The use of meta-analysis
for this project provided an opportunity to employ different statistical tools to assess the
ES of the treatment or examined intervention. It is the prudent tool to use in this type of
study as it allows for the analysis of a greater volume of subjects among several studies,
which are then analyzed simultaneously. The benefit of this analytical tool is in the
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aggregate data obtained which represents the magnitude and direction of the intervention
effects throughout all the applied studies (Wilson, 2010). This aggregate will
consequently provide better research data on the effect of the intervention (Wilson,
2010).
Utilizing meta-analysis allows for a detailed assessment of the influence of the
independent variable (IV) SDPs on the dependent variables (DV) which includes PSA
and E2. Age and other exposure factors were controlled during the analysis process and
therefore the data output was not affected or influenced by those factors (Wilson, 2010).
ES was determined using OR and other applicable statistics, including the standardized
mean difference (SMD), correlation coefficient (CC), and Hedges’ g (Wilson, 2010). It
was necessary that these standardized indexes be compared across the various studies.
They represented both magnitude and direction of the relationship investigated in the
studies analyzed and will be independent of sample sizes (Wilson, 2010). The metaanalysis software was able to compute ES through input of the means and standard
deviation data (Borenstein et al., 2007). However, this ability to use the software
interchangeably, can allow for individual usage while examining the relationship between
SDP intake and serum PSA and E2 levels (Neill, 2006). The use of the SMD for ES
calculation was obtained by dividing Differences in Score by the SD of applicable scores
(Neill, 2006). A presentation of the number of studies and effects used to generate the
meta-analysis and subsequently the ES and the CI will assist in valuing the reliability and
consistency presented through the ES mean (Neill, 2006).
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Analysis using the CMA software provided greater statistical reliability and
validity to the presented data. The result is the production of high quality reliable and
valid data. Presentation of the research design and methodology is further in this chapter.
Effect size computation formula:

There are also other statistical programs such as SPSS and SAS that could
effectively compute this study’s data output. However, the CMA software presented
earlier in this discussion, provides extensive analytical scope and was employed to
conduct all analysis. As an analytical tool it has all the required data applications that can
account for each measure of effect being determined (Becker, 1999). This is in fact
similar to calculating the degree of association between the independent variables and the
dependent variables (Becker, 1999). The ability to compare analysis using different
methods to achieve the goals can provide greater validity and reliability to the generated
results.
The statistical REM presents an opportunity to have a correlational deduction of
the ES of an individual intervention (Becker, 1999; Wilson, 2010). This study employed
OR using REM to define the correlation between variables. Other ES statistical methods
used included Hedges’ g, correlation r, and SMD (Konstantopolous, 2006). These
methods were applicable for this study as the selected RCTs are defined through
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treatment and control effect in different groups within the studied populations. Both
statistics are included among several accounted for in the CMA software. The formula
used for calculating SMD is

(Cochranes Handbook, 2010).
The SMD formula is also a representation of the expression of the size of the
intervention effect in each study relative to any variability that has been observed in a
particular study (Cochranes Handbook, 2010). In that context and in relation to ANOVA,
Eta squared ((h2) which represents total variance of an effect will be determined
employing the formula 2 = SSeffect / SStotal (Neill, 2006). In this formula SSeffect = ratio
of the effect variance and SStotal = total variance (Neill, 2006). However, the number of
independent variables accounted as well as the number and size of the effects (Becker,
1999) are influenced by p2. Variation in the size of the different SSeffect will also
influence the interaction effect result (Becker, 1999). Therefore, by using the above
method expressed earlier relating to variance exclusion by (Bowden, Tierney, Copas, &
Burdett, 2011) formula and the access to the professionally designed CMA statistical
software then the results should be able to demonstrate validity and reliability.
Internal and External Validity
Meta-analysis supplements considerably more validity and reliability to the data.
This supplementation has resulted in an increased use of meta-analysis especially in the
fields of medicine and public health where the effect of an intervention is the pertinent
response that is being sought. While there are weaknesses to the application of meta-
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analysis, the process can be considered valid and reliable and therefore, will prove a
valuable tool in this analytical process. Added validity and reliability will also be derived
from employing applications such as multiple regression to conduct aspects of the data
analysis. Adding to the validity and reliability of the data, will be the coding and the scale
used in conducting this research process. The continuous scale will be employed for this
process, since there will be an opportunity to consider the difference in means between a
treatment and a control group (Cochrane Collaboration, 2002). The value of having the
presence of associated data relating to sample size (s), mean (m) and standard deviation
data (SD) available from the research studies can also be appreciated as implied by
(Cochrane Collaboration, 2002), as invaluable to the employment of the continuous metaanalysis scale. While there might be immediate access to obtaining the standard deviation
from some studies it can easily be obtained from statistical manipulation of other
important variables such as the standard errors, confidence intervals, t-statistics, and pvalues (Cochrane Collaboration, 2002). Use of the professionally developed CMA
(MetaStat, 2007), software will be applied throughout this research.
Summary and Transition
This chapter presented important aspects of the research including the design of
the research process. Also addressed were the method of meta-analysis employed for this
study and the appropriateness of this method for this process. Chapter 4 will focus on
data presentation, interpretation of the results of the findings from the meta-analysis,
while Chapter 5 will focus on discussing those findings and making recommendations
based on those results. The conclusions that will be presented in Chapter 5, are those that

83
relate to the value of SDPs in alleviating the burden of CaP among the studied
population. Hopefully, the findings will generate invaluable recommendations that can
influence ‘positive social change’ within the broader community and even globally.
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Chapter 4: Study Findings
The purpose of this study was to determine the cumulative effect of genistein and
daidzein intervention on serum PSA and serum E2 levels in American men. This is a
cohort in which such analysis had not previously occurred. Guided by the principles of
primary and secondary prevention and the newly conceptualized model of cancer
prevention (DPIM), I sought to answer whether intake duration and concentration of
SDPs directly influence magnitude and direction of CaP response. A selected group of
eight RCTs of SDP CaP chemoprevention provided the data used in this study. These
studies represented interventions designed to prevent or delay progression of recently
diagnosed CaP disease or hormone-refractory CaP in men between 50–85 years old. This
chapter includes the characteristics of the randomized clinical trials, and the description
and tabulations of the hypotheses tested.
Characteristics of Randomized Clinical Trials
Information presented in this study includes data from eight (8) selected published
RCTs of men who have undergone SDP chemoprevention for newly diagnosed CaP,
hormone-refractory CaP and those at high risk for the disease following pathological
analysis. Studies had pre- and posttest information on at least one of the dependent
variables, PSA and E2, in order to be included. The studies selected were among some of
the most recent studies examining the association between SDPs and CaP
chemoprevention and the correlation to serum PSA and serum E2 levels. The studies
were published in peer-reviewed journals and dated from 2004 – 2012. Seven (7) trials
were conducted in the USA and one was conducted in research centers across Japan. The
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sample yielded 530 male participants ranging between the ages of 50-85 years who
matched selection criteria and completed baseline study requirements. The study
accounted for a decline in participants during follow-up and the analysis process.
The sample represents those that completed the clinical trial as both experimental
group and controls. Participants represented several ethnic groups including European
Americans, African Americans, Japanese Americans, Japanese, and Hispanics. However,
European Americans dominate the study samples and the group for which this analysis
needed to best address ES, African Americans, was not highly represented. Men with a
history of CaP with increasing PSA levels, and subjects with CaP diagnosis and with 3 –
6 months prior to surgical intervention, those monitored through active surveillance, and
HRC subjects have been included in this study. All groups have contributed to the
intervention and placebo groups that are the foundation of the study’s conceptualization
in relation to chemoprevention from SDPs. One RCT study reported an average age of
49.8 years old (White et al., 2010). Inclusion of this study should not significantly
influence data analysis. All studies reported data collection at baseline and 3 month
intervals. Incomplete study data due to non-compliance with study protocol following
selection and study commencement affected some study results. The lowest number of
participants in one study was 28 and the largest 158.
Table 1 provides a description of information abstracted from the eight studies
that were used to conduct the meta-analysis. Populations represented included those who
responded either positively or negatively within treatment group where intervention was
conducted. The odds of benefiting from intervention over placebo was then analyzed. The
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table was generated using meta-analysis and the REM statistics. This provided evidence
that contrasted the odds between the intervention and placebo groups in relation to
administering or lack of intervention. Studies 4 – 6 provided information on E2 response
to SDPs. Six (6) studies 1-3 and 6-8 provided evidence for PSA response to SDPs. The
odds of benefiting from SDP intervention in the Adams et al. (2004) study are 0.576
times more likely than the placebo. Benefit from SDP intervention is also seen in the
studies by Carmody et al. (2008), Schroeder et al. (2005), and White et al. (2010)
(OR=0.510, OR=0.667, and OR=0.700, respectively). However, the benefit of SDP
intervention is not seen in the Dalais et al. (2004), Hamilton-Reeves et al. (2004), and
Kumar et al. (2007) studies; the odds of SDP intervention influencing E2 levels are not
significantly different from those of the placebo group. These statistics are consistent
with OR analysis carried out using 2x2 contingency tables for hypotheses testing to
examine intervention or placebo on treatment and control groups. These findings using
SDPs as independent varialbes and PSA or E2 as dependent variables were determined
using both meta-analysis and 2x2 tables and both methods yielded statistical significance.
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Table 1
Events among Treatment and Placebo Groups to Determine OR and other Statistics by
PSA or E2 Outcome

Study
Authors
Adams et
al., 2004
Carmody et
al., 2008
Dalais et al.,
2004
HamiltonReeves,
2007
Kumar et al.,
2007
Miyanaga et
al., 2011
Schroder et
al., 2005
White et al.,
2010

PSA Outcome
E2 Outcome
Positive
Total
Positive
Total
Positive
Total
Positive
Exposure
n
Exposure
n
Exposure
n
Exposure
Treatment Exposed Placebo Placebo Treatment Exposed Placebo
34
17
47
14
-

Total
n
Placebo
-

10

17

5

14

-

-

-

-

7

8

8

8

-

-

-

-

-

-

-

-

4

12

0

17

-

-

-

-

3

22

1

27

3

75

2

78

14

33

16

47

3

17

4

16

2

24

3

25

14

24

8

25

18

25

7

25
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Among the studies selected for this meta-analysis, experimental participants
included those who had shown an increase in PSA levels following radical prostatectomy
or radiotherapy, participants who had recently undergone prostate biopsy and histological
analysis of the biopsied tissues, and men who were recently diagnosed through prostate
biopsy and histological analysis, above normal serum PSA levels in defined age groups,
pathology with CaP based on a defined inclusion Gleason Score and active surveillance.
These criteria have been important in contributing to the foundation of the study’s
conceptualization in relation to CaP chemoprevention from SDPs.
Statistical Meta-Analyses
The use of the REM in determining the ES and consequently the magnitude and
direction of the intervention accommodate all the in-study and between study concerns.
The REM accounts for any variance or bias in or between studies during the analysis
process. Bias was observed in the participant selection process through either low or noninclusion of some minority groups, especially African Americans who experience a
higher CaP incidence and disease burden (ACS, 2012).
The data analysis tool employed for conducting all aspects of this study was metaanalysis using OR statistic and following the constructs of the REM. This analysis was
able to address all univariate, multivariate and ES analysis. ES is important in
determining the magnitude and direction of the intervention. Two of the studies
accounted for more than two experimental groups and were therefore able to contribute
more value to the computed overall cumulative effect of genistein and daidzein on PSA.
Three (3) studies reported on E2 values pre- and postintervention and therefore were used
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to determine the effect of dietary and serum isoflavones levels on serum E2 levels. Seven
(7) studies reported on pre and post-test information on PSA. Results were determined on
the intervention effect response using genistein and daidzein. OR analysis was employed
to determine the ES of the treatment intervention with dietary SDPs and to understand the
correlation between dietary SDP, serum SDP levels, and serum PSA and E2 levels when
compared between treatment and placebo subjects. When using OR for ES determination
the results are defined through small = 1.50, medium = 2.50 and large = 4.50 odds ratio
that there is some odds that benefits from a treatment intervention might or might not
occur (Goldin, 2007). The ES as indicated was determined using the OR process but
other logarithmic approaches that corrected for bias in the data output were determined
from LogOdds Ratio, Variance, and Standard Error calculations.
Research Questions and Hypotheses
Research questions were answered using REM OR meta-analysis and OR 2x2
contingency table statistics. Both meta-analysis and 2x2 table computation resulted in
similar OR statistic results. The cumulative ES value from the meta-analysis provides
evidence that favours intervention. Intervention subjects showed that both PSA and E2
responded inversely to SDPs which would represent an inverse relationship. The output
data was generated using CMA software for ES and magnitude and direction of
individual study effect and for cumulative study determination. Odds ratio (OR) statistic
for correlation between independent and dependent variables based on the research
questions was performed using a 2x2 contingency table. Other statistics including
Hedges’ g, SMD and correlation were also used for meta-analysis data output (MetaStat,
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2008). All the studies selected had relevant data on the included variables. Independent
variables genistein and daidzein, and dependent variables PSA/E2 values were abstracted
from each individual study.
Odds (OR) of the effect of genistein and daidzein on the level of PSA and E2 as
evidence of chemoprevention of CaP are presented through the following research
questions, hypothesis and OR calculations. The OR provides information on the odds and
not the probability of an event occurrence within the treatment group. However, the Cox
Index which is determined through meta-analysis has been acknowledged as providing
ES information that is known to be unbiased and also provides the best information on
ES using continuous variables (TEA, 2011).
Research Question 1:
Is there a correlation between dietary SDPs and serum SDP levels?
Null Hypothesis H1o: There is no correlation between dietary SDP levels and
serum SDP levels.
Alternative Hypothesis H1A: There is a correlation between dietary SDP levels
and serum SDP levels.
Statistical Analysis:
As shown in Table 2, the OR = 0.5957 implies that the untreated SDP group
would be more likely to not experience change in serum SDP levels. Therefore the odds
are that dietary SDP levels more likely influence a change in the serum SDP levels
within the treatment group. Changes in serum SDP levels are more likely a direct result
from the intervention and not a chance occurrence This OR also indicates that at 95% CI
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there is a 0.2588 to 1.3712 increase of a positive outcome in the treatment group,
although this increase at the 5% level is not statistically significant (MedCalc, 2013).
This odds ratio therefore supports rejecting the Null hypothesis.
Table 2
Odds Ratio and 95% C.I. between Dietary SDP and Serum SDP Levels
SDP Serum
Outcome
Positive Negative
SDP Yes
34
17
SDP No
47
14
Totals
81
31

Odds
34/17
47/14
(34/17)/(47/17)

OR

95% CI

0.5957

[0.2588, 1.3712]

Research Question 2:
Is there a correlation between dietary SDPs and serum PSA levels?
Null Hypothesis H2o: There is no correlation between dietary SDP levels and
serum PSA levels.
Alternative Hypothesis H2A: There is a correlation between dietary SDP levels
and serum PSA levels.
Statistical Analysis:
As shown in Table 3 OR = 0.6667 and implies that the untreated SDP group
would be more likely to not experience change in serum PSA levels when compared to
the treatment group. Therefore the odds are that dietary SDP levels more likely influence
a change in the serum PSA levels within the treatment group. Changes in PSA level are
more likely a direct result from the intervention and not a chance occurrence. This OR
also indicates that at 95% CI of 0.1013 to 4.3878 there is some effect from treatment
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although outside the statistical significance level at 5% (MedCalc, 2013). This odds ratio
therefore supports rejecting the Null hypothesis.
Table 3
Odds Ratio and 95% C.I. between Dietary SDP and Serum PSA Levels
Serum PSA
Outcomes
Positive Negative
SDP Yes
22
3
SDP No
22
2
Totals
44
5
p-value=0.018

Odds
22/3
22/2
(22/3)/(22/2)

OR

95% CI

0.6377

[0.1013, 4.3878]

Research Question 3:
Is there a correlation between dietary SDPs and serum E2 levels?
Null Hypothesis H3o: There is no correlation between dietary SDP levels and
serum E2 levels.
Alternative Hypothesis H3A: There is a correlation between dietary SDP levels
and serum E2 levels.
Statistical Analysis:
Table 4 indicates the OR = 0.4259 and implies that the untreated SDP group
would be more likely to not experience change in serum E2 levels when compared to the
treatment group. Changes in E2 level are more likely a direct result of the SDP
intervention than from chance occurence. This OR also indicates that at 95% CI there is a
0.0362 to 5.0055 increase of a positive outcome within the treatment group. This also
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indicates a CI within the 5% level and therefore statistically significant (MedCalc, 2013).
This odds ratio therefore supports rejecting the Null hypothesis.
Table 4
Odds Ratio and 95% C.I. between Dietary SDP and Serum E2 Levels
Serum E2 Outcomes
Positive
SDP Yes
23
SDP No
27
Totals
50
p-value=0.050

Negative
2
1
3

Odds
23/2
27/1
(23/2)/(27/1)

OR

95% CI

0.4259

[0.0362, 5.0055]

Research Question 4:
Is there a correlation between serum SDPs and serum PSA levels?
Null Hypothesis H40: There is no correlation between serum SDP levels and
serum PSA levels.
Alternative Hypothesis H4A: There is a correlation between serum SDP levels and
serum PSA levels.
Statistical Analysis:
As shown in Table 5 an OR = 0.7000 implies that the untreated SDP group would
be more likely to not experience change in serum PSA levels. Therefore the odds are that
serum SDP levels is likely to influence a change in the serum PSA levels within the
treatment group. Changes in serum PSA level are more likely a direct result from the
intervention and not a chance occurrence. This OR also indicates that at 95% CI there is a
0.2024 to 2.4207 increase of a positive outcome in the treatment group at the 5%
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confidence level and therefore not statistically significant (MedCalc, 2013). This odds
ratio therefore supports rejecting the Null hypothesis.
Table 5
Odds Ratio and 95% C.I. between Serum SDP and Serum PSA Levels
Serum PSA
Outcomes
Positive Negative
SDP Yes
28
8
SDP No
25
5
Totals
53
13
p-value=0.018

Odds
28/8
25/5
(28/8)/(25/5)

OR

95% CI

0.7000

[0.2024, 2.4207]

Research Question 5:
Is there a correlation between serum SDPs and serum E2 levels?
Null Hypothesis H50: There is no correlation between serum SDP levels and
serum E2 levels.
Alternate Hypothesis H5A: There is a correlation between serum SDP levels and
serum E2 levels.
Statistical Analysis:
As shown in Table 6 an OR = 0.641 implies that the untreated SDP group would
be more likely to not experience change in serum E2 levels when compared to the
treatment group. Changes in serum E2 level are more likely a direct result from the
intervention and not a chance occurence. The OR also indicates that at 95% CI there is a
0.1042 to 3.9447 increase of a positive outcome within the treatment group. This increase
is at the 5% level and is statistically significant (MedCalc, 2013). This OR therefore
supports rejecting the Null hypothesis.
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Table 6
Odds Ratio and 95% C.I. between Serum SDP and Serum E2 Levels
Serum E2
Outcomes
Positive Negative
SDP Yes
75
3
SDP No
78
2
Totals
153
5
p-value=0.050

Odds
75/3
78/2
(75/3)/(78/2)

OR

95% CI

0.641

[0.1042, 3.9447]

Cumulative Effect of SDP on PSA and Estradiol
Six (6) RCTs were analyzed for consideration of the cumulative response to
treatment (Figure 8) from SDPs on serum PSA level. The SDP cumulative ES on sPSA
resulted in a positive correlation (OR=0.507, 95% CI [0.288, 0.891], p=.018). Another set
of five (5) studies were analyzed for consideration of the cumulative response to
treatment (Figure 9) from SDPs on sE2 level. The SDP cumulative ES on sE2 also
showed a positive correlation (OR=0.366, 95%CI [0.134,1.002], p=0.050). The ES of
each study’s dependent variable is represented by a square (■) where the size of the
squares contribute more and length and thickness of lines provide evidence of
contribution of each study towards cumulative ES. The diamond (♦) represents the
cumulative ES for the set of six (6) studies showing the PSA response and the other set of
five (5) studies showing E2 response. Further evidence of these correlations were
determined through other ES statistics and Forest Plots also generated by the metaanalysis software. These confirmatory findings will be discussed in Chapter 5. The
overall ES favoring the treatment or the placebo group is shown in the Forest Plot for the
PSA outcome (Figure 8) and E2 outcome (Figure 9).
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Study Authors

Statistics for each Study

Odds ratio and 95% CI

Odds Lower Upper
Ratio Limit Limit Z-Value p-Value
Adams
0.424
Carmody 0.389
Dalais
3.400
Miyanaga 0.632
Schroder 1.524
0.336
White
Cumulative 0.507

0.169
0.090
0.120
0.103
0.290
0.105
0.288

1.062
1.673
96.700
3.890
8.014
1.081
0.891

-1.831
-1.269
0.716
-0.495
0.497
-1.829
-2.362

0.067
0.204
0.474
0.620
0.619
0.067
0.018
0.01

0.1

1

10

100

Favors SDP Favors Placebo
Figure 8. Odds Ratios and 95% CI Effect Size of PSA Response to Phytoestrogen
Treatment using REM Meta-Analysis
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Study Authors

Statistics for each Study

Odds Ratio and 95% CI

Odds Lower Upper
Ratio Limit Limit p-Value Z-Value
Hamilton-Reeves0.054

Kumar
Miyanaga
Schroder
White
Cumulative

0.244
0.700
1.500
0.151
0.366

0.003
0.023
0.280
0.228
0.044
0.134

1.122
2.527
1.752
9.872
0.520
1.002

0.059
0.237
0.447
0.673
0.003
0.050

-1.886
-1.183
-0.761
0.422
-2.999
-1.957
0.01

0.1

1

10

100

Favors SDP Favors Placebo
Figure 9. Odds Ratios and 95% CI Effect Size of Estradiol Response to Phytoestrogen
Treatment using REM Meta-Analysis
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Heterogeneity
The use of heterogeneity provides a measure of inter-study variability, a major
consideration for meta-analysis. Heterogeneity helps to measure any inconsistencies that
might be present within the results obtained from analysis of the data within the six
studies used in each of the meta-analysis (StatsDirect Limited, 2011). The Heterogeneity
statistic in this study using the REM and odds ratio for ES analysis of PSA response was
significant at p=0.019 (Test of Null, 2-Tail). The Heterogeneity statistic using the REM
to calculate the OR for ES determination of E2 response was significant at p=0.049 (Test
of Null, 2-Tail). This heterogeneity function is used to denote the weight of a particular
study and I-squared (I2). I2 represents the percentage variation across studies due to
heterogeneity and not chance (StatsDirect Limited, 2011). Heterogeneity is considered to
influence when I2 reaches 75%.
Heterogeneity is represented statistically by Cochran’s Q. Q can be calculated by
employing the combined sum of the difference of squared effects of an individual study
and the effects which have been pooled across the studies (StatsDirect Limited, 2011).
The weight of the studies’ effect is also based on the pooling of those studies. Q‘s
distribution is statistically similar to the chi-square distribution with k being the number
of studies minus 1 degree of freedom (df). Because of the small amount of studies used in
this meta-analysis Q might not be very valuable for testing heterogeneity. Q could under
compensate in this study because of the small number of studies, or it could also overcompensate if the meta-analysis consisted of a large number of studies (SDL, 2011). I 2 is
therefore the important statistic that helps in the testing of heterogeneity. I2 indicates the
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percentage of variation that is seen across studies and is due to heterogeneity
rather than to chance (SDU, 2011). Heterogeneity is also important in that it includes
statistical, methodological, and clinical types of heterogeneity. Since heterogeneity
relates to those differences or variability that are present among different studies its use
provides value to the output data. Key differences that are important between study
participants are among those characteristics that account for the clinical heterogeneity
and is important to the foundation of this analysis process (Bandolier, 2007). Other key
differences between studies are also seen in areas such as the participants, the
intervention employed and the observed outcomes (Bandolier, 2007). The Q statistic is
calculated by employing the combined sum of the difference of squared effects of an
individual study and the effects pooled across studies (StatsDirect Limited, 2011). The
weight of the effects are mainly based on those pooled studies.
Important differences that existed between study participants included
characteristics that account for clinical heterogeneity and are the foundation of this
analysis (Bandolier, 2007). Key differences between studies are in areas such as the
participants, the intervention employed and the observed outcomes (Bandolier, 2007).
These are areas where the use of the random effect model becomes valuable. Other ES
calculations were done using different statistical methods including SMD, correlation,
Hedges’ g and risk ratio. The analyses using Hedges’ g and correlation are presentd as
Figures 11 and 12. They provide similarity to the correlation which had been determined
by odds ratio statistic.
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Summary and Transition
Consistent with the purpose of the study to determine the cumulative effect of
genistein and daidzein intervention on serum PSA and serum E2 levels, five research
questions were answered using OR and meta-analysis. The first research question sought
to determine if the correlation between dietary intake of SDPs translated into equivalent
absorption of serum SDPs. The odds ratio indicated a significant ES in the pooled
analysis of eight studies, and the null hypothesis was rejected. Overall, there was a
correlation between dietary SDP and serum levels of SDP. The second and third
questions sought to answer whether dietary SDPs were correlated with serum PSA and
E2 levels. Both the second and third null hypotheses were rejected as significant
correlations were determined based on OR for PSA at p=0.018, and OR for E2 at
p=0.050. The fourth and fifth research questions sought to answser whether serum SDPs
were correlated with serum PSA and E2 levels. Findings supported rejecting both null
hypotheses. There was a direct correlation betweeen serum SDP levels and response of
serum levels of PSA significance p=0.018, and E2 p=0.050.
The correlations were supported by evidence from OR 2x2 contigency table
analysis of treated and non-treated individuals and through OR, correlation, Hedges’ g
and SMD Forest Plot evidence. The cumulative ES supported by all the evidence
indicates that there were signifcant correlations between intervention compared to
placebo groups. Chapter 5 will provide further discussion on the results of these findings,
the implication for positive social change, limitations of the study and an overall
interpretation of the results.
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Chapter 5: Discussion, Conclusions, and Recommendations
Overview
The purpose of this study was to determine through cumulative evidence the
effect of using the SDPs genistein and daidzein on PSA and E2, important markers for
early diagnosed CaP and HRC CaP incidence in American men, a cohort where such
analysis has not previously occurred. The research process was guided by the principles
of primary and secondary prevention and the DPIM (Michelin & Gutierrez, 2013). I
sought to answer whether intake of SDPs directly influenced the magnitude and direction
of PSA and E2 levels which were important in CaP response to therapy and outcome.
Information for this study was obtained from selected published RCTs which used the
named SDPs in chemopreventive intervention designed to prevent or delay cancer
progression in recently diagnosed men or in men with HRCaP between 50–85 years old.
This study was a quantitative analysis of information from selected published
RCTs demonstrating the chemoprevention ability of soy derived SDPs. Analysis of the
ES of the intervention in these studies was conducted employing meta-analysis. The
independent variables are quintiles of the SDPs genistein and daidzein. The dependent
variables included serum levels of E2 and PSA. The study sought to determine the ES in
SDP dose-response intervention in the selected male populations during the therapeutic
application for recently diagnosed and recurrent CaP, and the contribution of duration
and concentration in determining the size and direction of action.
These OR ES statistics provided reliability to the correlations seen in the OR data
output. Other statistics that provide value and support the validity and reliability of the
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OR data output includes both Z and p values. Tables 2 through 6 are 2x2
tables that provide correlation of the response between independent and dependent
variables. The observed OR is determined at 95% CI for correlation between variables.
This provides valuable information on the intervention in relation to the
untreated/placebo group. OR = 1 implies no significant difference between treatment and
placebo group or no effect from treatment, where OR < 1 implies that the untreated group
will be more exposed to experiencing a negative response. An OR > 1 implies that the
treated group would more likely benefit from the intervention.
Confirmatory and Transitory Evidence
This study was guided by the principles of primary and secondary prevention
following the DPIM (Michelin & Gutierrez, 2013). This model is described in Figure 3
(page 15) and guided the examination of the research questions. These questions related
to the chemoprevention of CaP using SDPs. The model showed the potential for
therapeutic application. The direct influence of dietary SDPs on serum SDP levels and
the strength and direction of treatment on serum PSA and E2 levels was important. Both
serum PSA and E2 could influence CaP response and outcome. ES of treatment was
determined using OR, SMD, correlation, and Hedges’ g statistics.
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Table 7
REM Statistics for Computing Effect Size and Heterogeneity
Effect
Size
value

2 Tail
Null
Test pvalue

Hedges’ g

-0.368

0.019

3.792 0.000

-0.546

0.049

7.501 46.672 0.072

-0.184

0.015

3.861 0.000

-0.280

0.035

8.251 51.519 0.004

-0.375

0.018

3.747 0.000

-0.554

0.050

7.542 46.962 0.080

0.507

0.018

3.747 0.000

0.366

0.050

7.542 46.962 0.836

Hedges’g
Correlation
Correlation
SMD
SMD
OR
OR

Random
Effect(PSA)
Random
Effect(E2)
Random
Effect(PSA)
Random
Effect(E2)
Random
Effect(PSA)
Random
Effect(E2)
Random
Effect(PSA)
Random
Effect(E2)

Q

I2

Statistical Measures Meta-Analysis
of Effect Size
Model

Variance

0.010

0.001

0.011

0.121

There was significant difference between intervention and placebo. This was seen
in the OR REM produced forest plots (Figures 8 & 9), which favored intervention over
placebo. Other statistical ES tests including SMD, correlation and Hedges’ g provided
similar results. Forest plots representing Hedges’s g are shown on pages 107 and 108, and
for correlation on pages 109 and 110. The test for heterogeneity in the study supported
the results of ES analysis.
Determining Q can compensate for the limitations that could affect the data
obtained from the study. Accommodating limitations is possible using meta-analysis
(SDL, 2011). I 2 is also an important statistic that helps in the testing of heterogeneity. It
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indicates the percentage of variation that is seen across studies and which are
due to heterogeneity rather than by chance (SDU, 2011). Importantly, there are different
types of heterogeneity. These include statistical, methodological and clinical.
Heterogeneity relates to the differences or variability that is present among different
studies. In this study, I2 determined the estimate of effects in this study as represented
through the several interventions. During this study, individual investigations sought to
determine the effect of an intervention compared to placebo, indicating clinical
heterogeneity (Bandolier, 2007). Importantly, several studies employed the research
practice of adhering to the intention to treat (ITT) principle. This ITT allowed the
researchers to follow the subjects for the length of the research process (Lachin, 2000).
There are also important key differences between studies which are related to the
participants, the intervention employed and the observed outcomes. Some of these were
also observed in this study (Bandolier, 2007). Again, these are areas where the use of the
random effect model becomes valuable in helping to resolve issues that could be
associated with study differences.
The heterogeneity for studies used to determine the ES of PSA response with
OR statistic is represented by Q value=3.747, Q(df) =5 and I2=0.000, supports the
correlational significance determined through the ES analysis. The 2-tail null test for PSA
shows a negative Z value of -2.362 and a p=0.018 (Figure 8). Heterogeneity for studies
used to determine E2 response is represented by Q value of 7.542 Q(df)=4 and
I2=46.962, supports the correlational assessment determined through the ES analysis. The
2-tail null test for E2 shows a negative Z value of -1.957, and a p=0.050 (Figure 9). Some
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heterogeneity was observed between studies when E2 response was
determined. However, heterogeneity did not appear to influence either the results that
were determined during PSA and E2 response to SDP intervention. Since the OR Z value
-2.204 for PSA response is negative and outside the -1.96 and +1.96 normal distribution
with a p value 0.028, then these values appear to support a rejection of the null
hypothesis. There were no significant differences in the results obtained for PSA and E2
response using other ES statistical analyses. Using SMD to determine ES for E2 response
provided an overall p value of 0.050 and variance of 0.080 which as indicated is an effect
that is within the p < 0.05 significance level. A statistical significant p value =0.050
indicates the probability that any observed changes could be attributed to the intervention
rather than by chance occurrence (Thisted, 2010). Similarly, the overall significance level
for E2 determined from Hedges’g ES analysis is p = 0.027 (Figure 11). This implies a
statistically relevant correlation between SDP treated group and placebo groups, but
might still not provide sufficient evidence to eliminate some chance occurences (Thisted,
2010).
Overall, the data indicate that there is acceptance that intervention with SDPs for
PSA reduction and influencing increases in E2 levels can be important for CaP
chemoprevention. Such therapy can be accomodated within the putative model
(Giovannucci, 1999) and has the potential for improving health outcomes. The
correlation between dietary and serum SDPs, which results in an increase in the latter,
appears to have some beneficial role in modulating both serum PSA and E2. With serum
E2 maintaining a high level following intervention, the evidence supports its role as an
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estrogen replacement for CaP therapy. As a natural alternative source, it could
be effective in reducing present CaP incidence, especially in communities where
economic status does not allow for available medical interventions.
Interpretation of Key Findings
In this study, eight RCTs were used to calculate the ES of SDP in a
chemopreventive role in various conditions where the diagnosis of CaP was concluded.
To conduct ES of the intervention, the CMA software was used. The adverse events
within both treatment and placebo groups was used in a 2x2 cohort format to calculate
OR for ES and magnitude and direction of treatment intervention using meta-analysis.
REM was used in this study as it provided a more reliable approach for data analysis than
the FEM. REM is able to mitigate differences that are present within and between studies.
This accounts for the differences through a broader framework of understanding that
studies were done under different situations with different populations. Figures 8, 9, and
10 indicate individual and cumulative ES of treatment intervention. Table 8 reflect the
different outcomes relating to PSA and E2 response from SDP intervention. The
correlations seen between the DVs and IVs provides evidence of support or rejection of
the Null hypothesis for the Alternative hypothesis. As indicated an increase in sSDP, and
a subsequent decrease in sPSA and increase in sE2 then the Null Hypothesis is rejected.
Other conditions relating to the acceptance or rejection of the Null hypothesis for the
Alternative hypothesis are presented in the table.
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Table 8
Interpretation of Hypotheses Testing Results Using Random Effect Model Effect Size
Hypothesis
Testing

Accept Null (T)

Reject Null (F)

Accept Alternative
(T)

Reject Alternative
(F)

Dietary SDPs

↑ Serum levels

↓ Serum levels

↓ Serum levels

↓ Serum levels

Serum SDPs

↑ SDP

↑ SDP

↓ SDP

↓ SDP

Serum PSA

↓ PSA

↑ PSA

↑ PSA

↓ PSA

Serum E2

↑ E2

↓ E2

↓ E2

↑ E2

The various relationships indicated above in figure 8 are also a reflection of the
effect of dSDP and the serum level response of sSDP, sPSA and sE2. The cumulative
response to dSDP intervention is provided in Figures 10 and 11. Figures 10 and 11 are
representative Forest Plots that show the strength and direction of the contribution from
each study’s effect to the overall treatment effect on both PSA and E2. The contributory
effect of each study to the cumulative effect is identified through the size of each study’s
representative square and length and thickness of the effect line. The effect of dSDP and
subsequently sSDP appears to be significant and favors the use use of intervention during
CaP therapy where PSA and E2 responses are beneficial. The effect response of both
PSA and E2 to SDP over the time of the experiment are indicated in the two graphical
representations. These results were used to confirm similar correlation obtained from OR
analysis. Other ES statistics including Correlation and SMD were done and provided
similar positive results favoring SDP intervention. While those ES provided values within
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a different statistical context of a 95% CI all appeared to provide similar
supportive evidence for rejection or acceptance of the null hypotheses.
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Figure 10. Hedges’s g Assessment for Effect Size Statistic for PSA Response to Phytoestrogen
Treatment using REM Meta-Analysis
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Figure 11. Hedges’ g Assessment for Effect Size Statistic for Estradiol Response to Phytoestrogen
Treatment using REM Meta-Analysis
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Hedges’ g statistic using REM meta-analysis to test for E2
heterogeneity resulted in a p value = 0.049 (Figure 11), significant at the 95% CI level.
The analysis for E2 response determined that treated subjects had optimum response to
SDP significant at the p=0.050 level. A similar positive response was determined
regarding the PSA response to SDP intervention. Forest plots indicating the cumulative
effect of SDP on sPSA and sE2 are provided in Figures 12 and 13 respectively.
Correlation for PSA response was determined at the p=0.015 level. OR results had also
suggested that there were changes in relation to PSA status, which would suggest benefit
from the chemoprevention. Statistical significance for OR was determined to be p=0.018
as previously reported. While lower PSA levels do not always infer improved health
outcome during therapy, reduced levels can be seen as an important marker for overall
therapeutic response (NCI, 2012). In fact, some factors including age of subjects,
duration and concentration of treatment and size of experimental population could affect
OR results. These results appear to support the goal of this study and are within the
framework of the DPIM (Michelin & Gutierrez, 2013). The previous evidence may
provide for effective implementation of chemoprevention prior to disease development.
Findings from the various ES statistic supported rejecting the Null. These findings also
indicated the potential ability to reduce PSA levels within the population through
introduction of dietary SDP. The benefit of maintaining serum E2 concentrations also
appears to be a valuable outcome from SDP chemoprevention.
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Figure 12. Correlational Assessment for Effect Size Statistic for PSA Response to Phytoestrogen
Treatment using REM Meta-Analysis
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Figure 13. Correlational Assessment for Effect Size Statistic for Estradiol Response to Phytoestrogen
Treatment using REM Meta-Analysis
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This meta-analysis was conducted using exposure and non-exposure to treatment
and placebo groups. The results from the various meta-analysis statistics showed
differences in the between studies ES although all observed cumulative effect indicated a
rejection of the null hypothesis. The symbol which is representative of the cumulative ES
on the confidence level line was evidence of the correlation between SDP intervention
and estradiol (E2) and PSA response. This information is presented in Figure 11 with
graphical Forest Plot. The individual and cumulative contribution from each study is used
in determining ES and magnitude and direction of treatment effect. The studies by
(Carmody et al., 2008; Schroder et al., 2006; and White et al., 2010) appear to have
significant influence on the overall presented data. The presented data output is also a
representation of the effect of each study on the overall ES. This effect is repesented
through larger squares and shorter lines that are shown on each line which represents an
individual study. There appears to be no significant difference between the effects over
time as indicated between the two graphical representations. To confirm results that were
obtained from OR analysis, other ES statistics including Hedges’ g, correlation, and SMD
were done. While ES values were represented in different context of a 95% CI it
appeared that the overall evidence for rejection or acceptance of the Null hypotheses
indicated through were supportive.
Study Limitations
Bias could be attributed to study population selection and size since either could
influence data output. Evidence in the various studies show an increase in serum levels
from baseline to study completion. These changes are important in the effect analysis that
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is computed for independent and dependent variable effect. Implication from this study
seem to indicate that the intervention using soy derived SDPs does have some effect on
the treatment population. This difference was demonstrated through the analysis data on
both treatment and placebo or control groups in this study. However, further research
might be needed to determine the true value of genistein and daidzein the test
compounds. Within the context of these results and the overall framework of the research
model there was evidence that seem to indicate that there is value from the treatment.
However, other limitations might have resulted from issues with coding and data
transferring for the required meta-analysis. The data reported in the studies might also be
subjected to study bias and therefore did not provide the best evidence relating to benefits
of therapy when subjected to meta-analysis. While duration as a moderating variable did
not appear to have any significant effect on the magnitude and direction of the treatment
as seen in Figure 1, possible longer duration might have some effect. Another important
context to defining the significant difference between PSA treated and placebo groups is
indicated where p= 0. 018 (Figure 8) determined by OR REM statistic, p=0.019 (Figure
10) by Hedges’g REM statistic and p=0.018 determined by SMD REM statistic. These
values represent the probability that the response to treatment is different from only
chance ocurences. Statistical significance is observed at p values of < 0.01 or p < 0.001.
Similarly, it is also important to define the significant difference between E2 in treated
subjects and in untreated controls. Here, p=0.050 (figure 11) determined by OR REM
statistic, p=0.049 (figure 12) determined by Hedges’g REM statistic, and p=0.050,
determined by SMD REM statistic. Statistical significance observed at p values of < 0.01
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or p < 0.001. Statistical significance to SDP intervention was obtained through values for
PSA ES response at p=0.018 OR and for E2 ES at p=0.050 OR statistic. Statistical
significance at the p≤0.05 level was therefore indicated from these statistics.
Testing if studies used in the meta-analysis are looking at the same study effect is
done by examination of the test for heterogeneity (Higgins, Thompson, Deeks, & Altman,
2003). Heterogeneity is considered significant in determining the quality of this study.
Other statistical analyses also reported some important p values. Correlational analyses
using meta-analysis for PSA response provided a value p= 0.015 and variance = 0.001
and the cumulative meta-analysis using Hedges’g statistic for heterogeneity among
studies for E2 response indicated a p value = 0.050 and variance = 0.072. These findings
indicated that there were some differences in response between experimental and placebo
groups. The significance of the analysis is supported by the fact that all statistics used in
this meta-analysis resulted in significant p values below p≤0.05.
Effect Size Analyses
ES were calculated adjusting for moderator variables, including median age,
duration of intervention, ethnicity of participants, differences between baseline and poststudy PSA, baseline and post-study E2, and any correlation between changes following
SDP chemoprevention. While there were six studies that provided information on serum
PSA levels at baseline and other time points during the study, only five studies provided
information that could provide context to be used regarding the influence of SDP on E2
during ES data analysis. However, ES data did not change after input of any of the
moderator variables including SDP duration or quantity provided during the experimental
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intervention. There were also no significant differences in the data obtained using the
FEM and REM (models). The data presented in this discussion were obtained using
statistics determined through the REM which was mentioned earlier in Chapter 1 and
then discussed extensively in Chapter 3. Meta-analysis used the REM since it offered the
opportunity for providing more reliable and valid data.
As a reminder, the purpose of this study was to determine through cumulative
evidence the ES of intervention with genistein and daidzein SDPs on serum PSA and E2
levels in males who were experiencing rising PSA levels, undergoing active surveillance
following CaP diagnosis, and males recently diagnosed with CaP or with hormone
refractory CaP. The study was designed to look at the magnitude and direction of the
output ES in response to SDP chemoprevention. The ES observation was made through
changes seen primarily among American males, a cohort where such meta-analysis had
not previously occurred. The conceptual premise of the study was guided by the
principles of primary and secondary prevention adhering to the newly conceptualized
DPIM (Michelin & Gutierrez, 2013). The study also sought to answer whether intake
duration and concentration of SDPs had a direct influence on the magnitude and direction
of E2 and PSA response. The observations from this meta-analysis reflect changes in
PSA and E2 levels that occurred as a result of dietary SDP intervention during the
duration of the RCTs. Additional observations to correlate these changes in PSA and E2
levels during the course of regular treatment could provide further evidence of correlation
with actual disease outcome and whether there is improvement in health status.
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Data for this study were obtained from selected published RCTs of SDP
intervention designed to prevent or delay hormone-refractory CaP and recently diagnosed
CaP in males between 50–85 years old. The REM statistical method was used in the
process the data analysis and also provided information on heterogeneity between
indivudal study intervention and cumulative meta-analysis study results. It was noticeable
that REM did not differ significantly from the FEM statistics. There was an observed
difference in the REM and FEM findings comparing treatment and placebo groups in
relation to the total study populations. Hedges’ g and SMD statistics afforded additional
context assisted in the determination of ES by providing confirmatory analysis when OR
was used for ES statistical analysis. Information obtained from OR statistic was used to
determine rejection or acceptance of either the null or the alternative hypothesis.
Cumulative OR statistic from the REM analysis is provided in Figure 8 (Page 97).
The SD measure is determined based on similarity to values between -1 to 1. An
ES value closer to 1 is a determination that there is a larger difference in effect between
treatment and placebo group involved in the study. When ES was determined using
Hedges’s g, analysis of data reporting E2 levels, this showed a positive relationship. The
ES of studies by Miyanaga et al. (2011), Kumar et al. (2007), White et al., (2010),
Schroder et al., (2005), and Hamilton-Reeves et al. (2007) are represented by g = -0.194,
-0.766, -1.025, 0.220, and -1.568, respectively. Here, all values fell below .50 which
would imply a SD of one-half (1/2) while 1.0 would be representative of a SD of 1.0
between the two groups. However, the negative values between the groups that reported
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predominantly on PSA levels indicate a decisive lower SD between treatment and
placebo groups. Heterogeneity testing (using Hedges’ g REM) indicated a cumulative Q
value of 3.792 (p=0.019, df (Q)=5, and I2=0.000) and ES of -0.368. The findings from
heterogeneity testing implied that there was a 5% chance at 95% CI of a positive effect
due to SDP intervention. Also, the effect seen in this study was within that probability of
significance determined by the p=0.019 value using OR statistic.
Recommendations for Future Research
The DPIM proposed in this study by Michelin and Gutierrez (2013) provides an
avenue for exploring early intervention and subsequent therapeutic strategies with disease
onset. Prior frameworks including the putative model proposed by Giovannucci, (1999),
do not appear to consider early established dietary standards and a public health context
is not the conceptualized focus. The DPIM allows for intervention using SDPs at
different stages of CaP etiology. Early dietary interventions could prevent or delay the
development of PINs. The value of PINs and their importance to CaP etiology was
presented earlier in this research. SDP intake prior to PIN development and clinical
cancer diagnosis that is accompanied by increasing PSA levels would therefore be
prudent. With progression continued inclusion of dietary SDPs and subsequent increase
in serum SDP levels could also be suggested. Research is required to determine the
optimum serum level at which SDPs afford the best health outcomes. The cumulative OR
results do not appear to suggest any significant difference between treated and placebo
groups in lowering serum PSA levels. However, there is significance in the levels of E2
that results from intervention. Further research is required to understand in greater detail
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the role of E2 in cancer etiology, and how SDPs can positively influence its serum levels.
However, based on the results of this research a more prudent approach would be to
begin intervention through the development of established dietary levels which appear to
have value in observed relationship between SDPs, PSA and E2 levels.
The findings from this study indicate that there is an inverse correlation between
serum SDPs and response of serum E2 levels. This could be supportive evidence for the
chemopreventive role of dietary isoflavones. The DPIM therefore appears to be better
suited for chemoprevention at an earlier stage and potentially be a more effective
preventative approach. An indication for SDP intervention which appears to be beneficial
based on results from the research is that relating to E2 levels. E2 levels which represent
an estrogen which is found in minute quantities within the male can be seen as a health
hazard if there is an imbalance and larger than normal quantities are present. Within the
articles that focus on E2 levels at pre and post-intervention, there appear to be significant
change in E2 serum concentration levels which with ES measure using OR statistic. The
evidence of higher E2 levels post-intervention may suggest greater odds for increasing
and maintaining higher levels of E2 subsequent to SDP intake and increase in serum
levels. E2’s role in natural estrogen replacement is therefore a practical application and
other studies have shown benefits in treating CaP using E2 therapy (Strax, 2005). It could
therefore be implied that if a nutritional standard for E2 is established similar to those for
other nutritional supplements then this could be advised especially for males after 50
years old. In relation to the etiological model proposed by Giovannucci, (1999), there are
points within that model where supplementation could be administered. Although
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phytonutrients are seen as potential supplementation prior to PSA increase and the
development of PINs which are important in the diagnosis of CaP, such intervention
might act as a suitable prevention modality.
Implications for Social Change
The results appear to support the evidence that factors associated with CaP
outcome such as PSA and E2 levels are influenced by isoflavone intervention that might
provide an effective chemoprevention approach. The approach to determine the
appropriate stage for chemoprevention is therefore the practical social change implication
to which these findings should be focused. This study determined that participants
undergoing SDP chemoprevention are ten times more likely to have higher levels of
serum E2 than the control group. Therefore, social implications for a nutritional standard
for E2 can be established similar to those for other nutritional supplements, especially for
males 50 years and older. The study also has relevance to members of different ethnic
groups who have higher incidence of CaP. Finally, the incidence of CaP continues to be
greater in later age decades and the growing aging of the population and increased life
expectancy require acceptable alternative prevention methods of prostate abnormalities.
Conclusion
The purpose of this meta-analysis was to determine the cumulative ES of eight
randomized clinical trials where the experimental group received SDP as secondary
prevention of CaP. From a clinical standpoint, the intervention is successful if the PSA
levels are improved. While there has been valuable information gathered from this study,
the need for additional research is warranted to conclusively determine SDPs role in
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reducing PSA levels. Larger sample size of experimental groups as well as other factors
such as duration and concentration of SDPs can be further explored. The results seem to
acknowledge the benefits of E2 in cancer prevention and thus more rigorous exploration
is recommended. The value as an SDP oral supplement or in hormonal replacement
therapy for CaP and other cancers is worth pursuing. Studies that seek to understand the
dynamics of a balance between PSA and E2 might also be invaluable to understanding
therapeutic and chemo-preventive properties.
More importantly, the results obtained from this analysis indicate the potential
benefit of SDPs in the primary prevention of CaP. A new model to illustrate the role of
the implementation of earlier intervention was designed. The proposed model was
developed as The Dual Prevention Intervention Model, consisting of a dual prevention
strategy. The access to intervention in this new model is conceptualized to provide
options for SDP chemoprevention. Chemoprevention appears to occur through two
defined strategies. First, the critical point at which primary prevention can be targeted
through SDP to prevent any cellular damage to prostate tissue, and second, identification
of the critical point at which secondary prevention can be targeted. In the present study,
RCTs aimed at using SDPs as chemoprevention of further prostate disease or prevention
of recurrent disease were assessed. The literature to date had not examined the role of
SDP as primary prevention nor as secondary prevention within a public health
framework. Although the findings of the correlation between direct intervention with
SDPs and serum PSA was not statistically significant, the findings indicate that
addressing secondary prevention can result in a change in serum PSA level towards the
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desirec clinical direction of a lowered level. Secondly, serum SDP appears to have a
direct influence on serum E2 levels which appear to be valuable for CaP outcome. The
approach using this model is to provide optimum chemoprevention with the potential for
improved health outcomes. The correlation between dietary and serum SDPs and
subsequently the effect on both sPSA and sE2 for cancer chemoprevention appears to be
supported by ES results. Moderator variables including intervention duration, quantity
and concentration of experimental variables, and age did not show any significant effect
on ES data. The test for heterogeneity was determined at 95% CI.
The data inidcated that the level of sE2 maintained following SDP intervention,
supports SDPs as valuable for estrogen replacement therapy. Estrogen replacement is
presently a valuable therapeutic straegy for CaP treatment. As a natural alternative source
it could be effective in reducing present incidence of CaP especially in poorer
communities. Many underserved communities do not have access to medical care
because of the lower socioeconomic status. Acess to early screening, preventive public
health methods and subsequent medical intervention is lacking and results in greater
disease burden and poorer health outcomes, especially among African Americans who
suffer from the greates incidence and mortality from CaP.
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Appendix A: Manual and Study Inclusion Form
Intervention Characteristics of Study: Selected studies should be RCT designed. Study
should specifically show intervention from use of the phytoestrogens (isoflavones)
genistein and daidzein among the components. Response of PSA and Estradiol in
treatment or placebo should be the primary main dependent variables been studied. They
are the important variables for the intervention strategy and are the primary measured
variables. Their association relating to effect size or magnitude and direction of treatment
effect and CaP chemoprevention is important.
Research Subjects: The RCTs should include subjects that are over 50 years old.
However as indicated prior one study had an age range between 49.8 and 85.4 years old.
Valuable study variables: These should include the independent variable isoflavones
(genistein and daidzein) and dependent variables PSA and estradiol.
Research methods: Studies needed to have both treatment and placebo groups. Baseline,
pre-study, post-study information throughout the study was important. However, any lack
of information on after study completion regarding follow-up would not deter selection.
The treatment group should be matched by a placebo or control group that remain absent
of any similarity to the employed treatment strategy.
Cultural and Language Concerns: Studies should be published in an English scientific
peer-reviewed journal. Publications can be from any country where such research was
conducted.
Publication Type: Primarily peer-reviewed RCTs
Publication time frame: Published within the past 15 years.

Coding Form
Study ID: Publication Type – Published scientific journal articles
Study Description: Randomized-controlled trials (RCTs)
Study Setting: Studies were conducted in several settings including medical and radiation
oncology clinics; Urology clinics, Minnesota Veterans Administration medical Center;
local urologists; Gastroenterology clinics; Los Angeles surgical patients; Local hospitals;
University of Massachusetts Teaching Hospital; University of California, Davis; Moffitt
Community Clinical Oncology program, Florida.
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Age Range of Participants:
Mean Age of Participants:
Standard Deviation:
Target Population:
i)
universal
ii)
selective
iii)
inclusive
Total confidence of target population: very weak; weak, moderate, strong, very strong
Total sample size (beginning of study (BS)):
Treatment group at BS:
Control group at BS:
Events: Reported study events
Adverse events (AEs):
Intervention Type:
i)
effect identification;
ii)
magnitude of effect;
iii)
direction of effect
Intervention strategy Assurance/Confidence:
i)
very low confidence;
ii)
low confidence;
iii)
moderate confidence;
iv)
high confidence; and
v)
very high confidence
Did information associating Phytoestrogens (Daidzein & Genistein) with PSA and
estradiol responses identified in the studies?
1) Yes – in all studies
2) No – in most studies; in a few studies
3) Some exclusions
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Nature of the control groups:
a)
b)
c)
d)

No treatment
Mixed
Placebo
Other (specify)
a. time-delayed;
b. volume-delayed;
c. concentration-delayed

Duration of Intervention: (days; weeks; months; and years)
a) Single session (specify)
b) Multiple sessions (specify)
c) Continuous sessions (specify if applicable)
Length of treatment:
Length of control:
Length of follow-up:
Total length of study and follow-up (if applicable):
Periods of assessment:
Pre-test, post-test
Post-test only
Pre-test, post-test, follow-up
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Appendix B: Effect Size Criteria Description
Intervention Criteria

Assigned #
for Criteria

Description of Criteria

Intervention characteristics

1

Both daidzein and genistein used in intervention

2

Only one isoflavone used in intervention

3

None used

4

Different isoflavones

5

Diagnosed with CaP or HRC

6

Undergoing therapy or scheduled for surgery/therapies
with increasing PSA

7

Completed therapy/active surveillance with increasing
PSA

8

PSA levels

9

Estradiol levels

10

Available data for computing Effect Size data

11

Meets the requirements for designing and conducting
RCTs including randomization and blinding process

12

Experimental groupings including Treatment and
placebo/control subjects

13

Presently available statistics employed in data analysis

Language/Cultural
Requirements

14

Unpublished or published in English

Published or unpublished
Time Frame

15

≤ 15 years ie. 1999 and later publications or unpublished
work

Publication Type

16

Publication in peer-reviewed scientific journal

Respondents to Research

Primary Variables

Research Methodology
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Appendix C: Effect Size and Study Coding Form
Study Level Coding
Level of effect size coding
1. Study ID
2. Effect size variables
Duration of phytoestrogen therapy
Concentration of components
3. Type of effect size
a. 2 groups -- contrast in groups
b. 3 or more groups -- contrast among groups
4. Effect size data page
5. Data providing Effect size:
a. Means and SD
b. t-value
c. Correlation
d. Hedges g
e. Others
6. Contrast in group designs:
7. Sample size (N)
8. Pre-Intervention Means
9. Post-Intervention Means
10. SDs
11. Pooled Variance
12. ES uncorrected
13. Values of Effect Sizes
14. Corrected SMD
15. Standard Error of Means
16. Inverse variance (weight)
Characteristics and descriptive feature of study
1. Bibliography
2. Study
3. Format published a) journal; b) unpublished
4. Country published
5. Year published
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Features of publication methodology
1. Study Design
a. Experimental;
b. Quasi-experiment;
c. Cross-over
2. Control group
a. Similar intervention;
b. Placebo;
c. Other treatment;
d. No treatment
6. Study Design
a. Experiment;
b. Quasi-experiment
c. Cross-over
d. RCT
7. Diagnostic and assessment instruments for CaP diagnosis
8. Blinding of Researcher
a. Yes;
b. Nno;
c. Partial, and
d. Not reported
Subject Assignment in study
a) Random
b) Non-random (explain)
c) Other i.e. Cross-over (explain)
Defining CaP inclusion threshold:
a) Yes: indicate methods
b) No: indicate methods
Timelines for Data collection
a) Baseline/pre-treatment
b) During treatment
c) Post-treatment
d) Follow-up
Role of experimenter during treatment
a) Provides treatment
b) Non-contact with subjects
c) Directed treatment
d) Uncertain i.e. not reported
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Appendix D: Permission to Use REM Figure

Subject :

Re: re. Use of Random Effects Model
figure

Date :
From :
To :

Tue, May 21, 2013 09:02 AM CDT
Michael Borenstein <MichaelB@Meta-Analysis.com>
Ruel Michelin <ruel.michelin@waldenu.edu>

Thank you for your note.
You are welcome to use any results achieved from our software,
however, please be sure to cite our program as follows:
Comprehensive Meta Analysis Version 2
Borenstein, M., Hedges, L., Higgins, J., & Rothstein, H.
Biostat, Englewood, NJ 2005
Thank you again.
Vivian Vargas
Assistant Administrator

At 07:42 PM 5/20/2013, you wrote:
>Dear Dr. Borenstein,
>
Good day. I would be extremely
> appreciative if you could provide an email or attached word
> document response giving permission to use a copy of your random
> effects model figure in the dissertation research document been
> prepared for ProQuest submission. Your quick response will be
> highly appreciated.
>
>Respectfully,
>Ruel Michelin.
>
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